documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii proxy statement filed march part item business separation abbott laboratories january abbvie became independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbott shareholder record close business december record date received one share abbvie common stock abbott common share held record date abbvie incorporated delaware april comprised abbott 's former researchbased pharmaceuticals business abbvie 's registration statement form declared effective us securities exchange commission december abbvie 's common stock began trading regular way ticker symbol abbv new york stock exchange january overview abbvie global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie products used treat rheumatoid arthritis psoriasis crohn 's disease hiv cystic fibrosis complications low testosterone thyroid disease parkinson 's disease ulcerative colitis complications associated chronic kidney disease among indications abbvie also pipeline promising new medicines including compounds indications phase ii phase iii development across important medical specialties immunology renal care hepatitis c women 's health oncology neuroscience including multiple sclerosis alzheimer 's disease acquisitions us pharmaceuticals business solvay pharmaceuticals facet biotech corporation added several new products abbvie 's portfolio including us rights androgel creon enhanced abbvie 's early midstage investigational pipeline adding investigational biologic multiple sclerosis compounds complement abbvie 's oncology program acquisitions discussed fully note acquisitions collaborations arrangements notes combined financial statements segments abbvie operates one business segmentpharmaceutical products incorporated herein reference note entitled segment geographic area information notes combined financial statements included item financial statements supplementary data sales information related humira included financial review products abbvie 's portfolio proprietary products includes broad line adult pediatric pharmaceuticals used throughout text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidated subsidiaries context requires humira humira biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union crohn 's disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthritis european union pediatric crohn 's disease severe european union humira also approved markets including japan brazil australia humira introduced market january worldwide sales grown approximately billion compared billion billion humira accounted approximately percent abbvie 's total sales united states composition matter compound patent covering adalimumab expected expire december equivalent european union patent expected expire majority eu countries april abbvie continues dedicate substantial research development efforts expanding indications humira including fields rheumatology peripheral spondyloarthritis axial spondyloarthritis pediatric enthesitis related arthritis gastroenterology pediatric crohn 's disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase iii trials ongoing preparation regulatory applications uveitis united states european union peripheral axial spondyloarthritis united states peripheral spondyloarthritis european union hidradenitis suppurativa united states european union metabolicshormones products metabolic hormone products target number conditions including exocrine pancreatic insufficiency testosterone deficiency hypothyroidism generated combined sales billion products include synthroid synthroid used treatment hypothyroidism abbvie 's sales synthroid totaled million androgel androgel daily testosterone replacement therapy available two strengths percent percent abbvie 's sales androgel totaled billion creon creon pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions abbvie 's sales creon totaled million abbvie rights sell synthroid androgel creon united states virology products abbvie 's virology products include two products treatment hiv infection kaletra norvir worldwide sales products billion kaletra kaletra also marketed aluvia emerging markets prescription antihiv medicine contains two protease inhibitors lopinavir ritonavir kaletra used antihiv medications increase chance treatment response people hiv abbvie 's sales kaletra totaled billion norvir norvir ritonavir protease inhibitor indicated combination antiretroviral agents treatment hiv infection abbvie 's sales norvir totaled million endocrinology products lupron also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection lupron generated sales approximately million select markets worldwide dyslipidemia products abbvie 's dyslipidemia products address range metabolic conditions characterized high cholesterol andor high triglycerides products generated sales billion primarily marketed primary care physicians include tricor trilipix tricor trilipix fibric acid derivatives indicated adjuncts diet reduce total cholesterol ldl cholesterol triglyceride levels key contributors cardiovascular disease increase hdl cholesterol levels abbvie rights sell tricor trilipix united states abbvie 's combined sales tricor trilipix totaled billion niaspan niaspan extended release form niacin indicated adjunct diet reduce total cholesterol ldl cholesterol triglyceride levels increase hdl cholesterol levels abbvie rights sell niaspan united states abbvie 's sales niaspan totaled million products abbvie 's products include following synagis synagis product marketed abbvie outside united states protects atrisk infants severe respiratory disease respiratory syncytial virus rsv abbvie 's sales synagis totaled million anesthesia products sevoflurane sold trademarks ultane sevorane anesthesia product abbvie sells worldwide human use abbvie 's sales sevoflurane totaled million duodopa duopa duodopa levodopacarbidopa intestinal gel lcig marketed outside united states treat advanced parkinson 's disease abbvie 's sales duodopa totaled million lcig therapy completed phase iii development united states name duopa abbvie pursuing regulatory approval united states zemplar zemplar product sold worldwide prevention treatment secondary hyperparathyroidism associated stage chronic kidney disease ckd abbvie 's sales zemplar totaled million research development activities abbvie numerous compounds clinical development including potential treatments highly prevalent conditions past five years abbvie doubled number compounds pipeline mix internal development external collaboration efforts abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase iinvolves first human tests small number healthy volunteers patients assess safety tolerability potential dosing phase iitests molecule 's efficacy disease relatively small group patients phase iiitests molecule demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety based regulatory criteria clinical trials development phases provide data required prepare submit new drug application nda biological license application bla submission regulatory approval us food drug administration fda similar government agencies outside us specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions research development process discovery new drug launch typically takes years even longer significant amount uncertainty inherent research development new pharmaceutical products guarantee molecule receive regulatory approval required launch new drug indication addition development new products new formulations research development projects also may include phase iv trials sometimes called postmarketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug abbvie spent approximately billion billion billion research discover develop new products indications processes improve existing products processes expenses consisted primarily collaboration fees expenses salaries related expenses personnel license fees consulting payments contract research manufacturing costs laboratory equipment facilities intellectual property protection regulatory exclusivity generally upon approval products development may entitled exclusivity applicable intellectual property regulatory regimes abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents filed june years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration patents products processes making product regulated federal food drug cosmetic act length patent extension roughly based percent period time filing investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities varies united states jurisdictions united states fda approves product contain previously approved active ingredient product typically entitled five years market exclusivity products may entitled three years market exclusivity approval based fda 's reliance new clinical studies submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days longest existing exclusivity patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years market exclusivity applicable laws regulations dictate market exclusivity product entitled upon approval particular country certain instances regulatory exclusivity may protect product patent protection longer available period time excess patent protection possible estimate product development total period exclusivity may become entitled regulatory approval obtained however given length time required complete clinical development pharmaceutical product minimum maximum periods exclusivity might achieved individual case would expected exceed three years respectively estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic followon product expiration applicable patent regulatory exclusivity periods biologics humira entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years exclusivity innovator biologic potential additional dayextension term conducting pediatric studies law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led greater regulatory scrutiny rigorous requirements approval followon biosimilar products smallmolecule generic pharmaceutical products also reduced effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications principal trademarks products cover discussed description abbvie 's products abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period aggregate believed material importance operation abbvie 's business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation company 's business whole united states composition matter compound patent covering adalimumab expected expire december equivalent european union patent expected expire majority eu countries april addition following patents licenses trademarks significant related lopinavirritonavir sold trademarks kaletra aluvia related fibric acid derivatives sold trademarks tricor trilipix related niacin sold trademarks niaspan simcor related testosterone sold trademark androgel united states composition matter patent covering lopinavir expected expire principal united states noncomposition matter patent covering lopinavirritonavir expected expire principal united states noncomposition matter patents covering fibric acid derivative products expected expire principal united states noncomposition matter patents covering niacin products expected expire principal noncomposition matter patent covering androgel expected expire percent formulation due pediatric exclusivity percent formulation agreements may affect exclusivity discussed item management 's discussion analysis financial condition results operationsresults operations abbvie may rely circumstances trade secrets protect technology however trade secrets difficult protect abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvie 's trade secrets may otherwise become known independently discovered competitors extent abbvie 's employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions sales marketing distribution capabilities abbvie 's products sold countries abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies three wholesale distributors accounted substantially abbvie 's sales united states sales mckesson corporation cardinal health inc amerisourcebergen corporation accounted percent percent percent respectively abbvie 's gross sales united states wholesalers purchase product abbvie standard terms conditions sale abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians key opinion leaders health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although company 's products must sold pursuant prescription united states outside united states abbvie focuses marketing efforts key opinion leaders payors physicians country regulatory bodies abbvie also provides patient support programs closely related products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses outside united states sales made either directly customers distributors depending market served approximately percent sales outside united states made wholesalers distributors wholesaler distributor outside united states accounts percent abbvie 's sales certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government third party agreements abbvie agreements third parties process development analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source example filling packaging humira syringes sold outside united states puerto rico performed single supplier two different facilities abbvie currently believe agreement material abbvie 's business substantially dependent upon abbvie maintains significant inventory humira syringes reduce risk supply disruption awaiting regulatory approval syringefilling packaging facility united states supply syringes outside united states puerto rico facility already approved provide product united states puerto rico addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services distribution logistics services certain products abbvie believe manufacturingrelated agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie also maintains sufficient inventory product minimize impact supply disruption abbvie also collaboration agreements discussed note acquisitions collaborations arrangements notes combined financial statements certain agreements abbott described item certain relationships related transactions director independence sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world including united states recent significant availability problems supply shortages orders orders generally filled current basis order backlog material abbvie 's business environmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital operating expenditures pollution control approximately million million respectively capital operating expenditures pollution control estimated approximately million million respectively abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments abbvie 's dyslipidemia products face competition fibrates statins search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection biosimilars competition abbvie 's biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate advent biologics also raised complex regulatory issues significant pharmacoeconomic concerns cost developing producing biologic therapies typically dramatically higher conventional small molecule medications many expensive biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products significant investments marketing distribution sales organization activities may limit number biosimilar competitors united states fda regulates biologics federal food drug cosmetic act public health service act implementing regulations enactment federal health care reform legislation march meant provide pathway approval biosimilars public health service act recent regulatory guidance suggests approval process biosimilars far extensive approval process generic followon versions small molecule products order ensure safety efficacy biosimilars highly similar original biologic humira ultimate approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency types data could ordinarily required application show similarity would include analytical data studies demonstrate chemical similarity animal studies including toxicity studies clinical studies applicable regulations also require biosimilar must indication original biologic involve mechanism action manufacturing facility meets standards necessary assure biosimilar safe pure potent furthermore new law provides biosimilar product deemed interchangeable may substituted original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching new law beginning interpreted implemented fda result ultimate impact implementation meaning likely subject substantial uncertainty years come european union pathway approval biosimilars existed since products come market date mixed impact market share incumbent products significant variation product competitive products although number competitive biologic branded products approved since humira first introduced gained modest share worldwide market addition first jak inhibitor part new class orally administered class products recently approved use rheumatoid arthritis us regulatory review europe abbvie continue face competitive pressure biologics orally administered products regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests obtain fda approval commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted three sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda biologic listing application bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional labeling also quality control manufacturing procedures must continue conform cgmp approval fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural substantive record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization postapproval regulatory obligations cost complying obligations could expand future outside united states abbvie subject similar regulations outside united states abbvie must obtain approval clinical trial application product applicable regulatory authorities commence clinical trials marketing product approval requirements process vary time required obtain approval may longer shorter required fda approval example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda bridging studies demonstrate foreign clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states country begin complete regulatory review process countries also require local clinical studies conducted order obtain regulatory approval country requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted eu periodic safety reports must submitted pharmacovigilance measures must implemented regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user establishment fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies call question utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payors providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceuticals manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries act also established b drug discount program requires pharmaceuticals manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price asp plus certain percentage account physician administration costs recently reduced hospital outpatient setting end stage renal disease treatment covered bundled payment likewise creates incentives providers demand lower pharmaceutical prices medicare enters contracts private plans negotiate prices patientadministered medicine delivered part march congress enacted patient protection affordable care act health care education reconciliation act together affordable care act affordable care act abbvie pays fee related pharmaceuticals sales government programs also abbvie began providing discount percent branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid starting record transfers value physicians teaching hospitals report data beginning centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties abbvie expects debate continue government levels worldwide marketing availability method delivery payment health care products services abbvie believes future legislation regulation markets serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure possible predict extent abbvie health care industry general might affected matters discussed abbvie subject corporate integrity agreement cia entered abbott may requires enhancements abbvie 's compliance program contains reporting obligations including disclosure financial payments doctors abbvie fails comply cia office inspector general us department health human services may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid european union eu adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout eu permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within eu lead significant parallel trade pharmaceutical products governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion generic alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action employees abbvie employed approximately persons january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website wwwabbvieinvestorcom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition risk factors generally separated three groups risks related abbvie 's business risks related abbvie 's recent separation abbott risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods following risks uncertainties develops actual events events could material adverse effect abbvie 's business financial condition results operations case trading price abbvie 's common stock could decline risks related abbvie 's business expiration loss patent protection licenses may adversely affect abbvie 's future revenues operating income abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs proposals enacted law could worsen effect generic competition abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings us composition matter patent humira abbvie 's largest selling product worldwide sales approximately billion expected expire december equivalent european union patent expected expire majority eu countries april humira biologic biologics readily substituted uncertain impact loss patent protection would sales humira abbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's future revenues operating income third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications andas united states food drug administration fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed example certain companies filed andas seeking approval market generic versions fenofibric acid capsules trilipix niacin extended release tablets niaspan companies asserted abbvie patents covering products invalid unenforceable andor infringed respective products abbvie entered settlement agreements resolving substantially challenges description material pending challenges please refer item legal proceedings although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses could diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's future revenues operating income reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's future profitability financial condition third parties may claim abbvie product infringes upon intellectual property resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition significant event adversely affects humira revenues could material negative impact abbvie 's results operations cash flows humira generates approximately percent abbvie 's sales significant event adversely affects humira 's revenues could material adverse impact abbvie 's operations cash flows events could include loss patent protection humira approval biosimilars humira discovery previously unknown side effects impaired efficacy increased competition introduction new effective less expensive treatments discontinuation removal market humira reason abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenue profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace sales profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful example abbvie discontinued development abt phase ii development treatment hematologic malignancies high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical preclinical outcomes beyond current standard care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's future results even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances pharmaceuticals biotechnology companies portion products nearterm pharmaceutical pipeline example abbvie collaborating biogen idec develop treatment relapsing remitting form ms also collaborating bristolmyers squibb treatment multiple myeloma biotest ag compound rheumatoid arthritis psoriasis failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products lead lengthy expensive litigation arbitration biologics carry unique risks uncertainties could negative impact future results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humira could adversely impact abbvie 's business results operations new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments abbvie 's dyslipidemia products face competition fibrates statins competitors may introduce new products develop technological advances compete abbvie 's products therapeutic areas immunology virology renal disease dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices superior performance features abbvie 's products could negatively impact abbvie 's business results operations abbvie 's biologic products may become subject competition biosimilars biologics price competition innovation act passed march title vii patient protection affordable care act law created framework approval biosimilars united states could allow competitors reference data biologic products already approved europe european commission granted marketing authorizations several biosimilars pursuant set general product classspecific guidelines biosimilar approvals issued past years addition companies developing biosimilars countries could compete abbvie 's biologic products competitors able obtain marketing approval biosimilars referencing abbvie 's biologic products abbvie 's products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenge abbvie 's applicable patent rights could also trigger competition products assuming relevant exclusivity period expired result abbvie could face litigation respect validity andor scope patents relating biologic products manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie relies single sources supply certain products services interruption supply products services could adversely affect abbvie 's business results operations abbvie single source supply certain products services example filling packaging humira syringes sold outside united states puerto rico performed single supplier two different facilities abbvie maintains significant inventory humira syringes intended reduce risk supply disruption awaiting regulatory approval syringefilling packaging facility united states supply syringes outside united states puerto rico abbvie also uses number products manufacturing process humira currently sourced single suppliers abbvie believes alternative sources products used manufacturing process humira currently available failure singlesource supplier fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations finding alternative supplier could take significant amount time involve significant expense due nature services need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives abbvie however carry business interruption insurance provides degree protection case failure singlesource supplier significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients investigators may also conduct additional perhaps extensive studies addition due various product withdrawals significant safety issues related pharmaceutical products amount time obtain regulatory approval increased industrywide health authorities rereviewing select products already marketed new safety efficacy issues reported new scientific information becomes available including results postmarketing phase iv trials changes government standards regarding safety efficacy labeling abbvie may required amend conditions use product fda authority based new clinical scientific information require postmarketing studies clinical trials labeling changes compliance fda approved risk evaluation mitigation strategies fda 's exercise authority could result delays increased costs product development clinical trials regulatory review increased costs comply additional postapproval regulatory requirements potential restrictions marketing approved products regulatory agencies outside united states often similar authority new safety data may emerge adverse event reports postmarketing studies whether conducted abbvie others whether mandated regulatory agencies voluntary sources may adversely affect sales abbvie 's products example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance serious safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance abbvie 's products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due real perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's products products companies promotes resulted could result unsafe condition injury patients product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business reputation ability attract retain customers consequences may also include additional costs decrease market share products lower income exposure claims product liability losses selfinsured product liability claims could material adverse effect abbvie 's business results operations abbvie subject costcontainment efforts pricing pressures could cause reduction future revenues operating income costcontainment efforts governments private organizations described greater detail item businessregulationcommercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's future revenues operating income reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future united states practices managed care groups institutional governmental purchasers us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressures recently enacted changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result additional pricing pressures numerous major markets worldwide government plays significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular governmentmandated price reductions many pharmaceutical products many european countries abbvie anticipates continuing pricing pressures europe differences countries pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction future revenues operating income abbvie subject numerous governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item business regulationdiscovery clinical development process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals might granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising postmarketing reporting including adverse event reports field alerts due manufacturing quality concerns many abbvie 's facilities procedures suppliers also subject ongoing regulation including periodic inspection regulatory authorities abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions event noncompliance could include warning letters fines damages injunctions civil penalties recalls seizures abbvie 's products criminal prosecution actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining government benefit programs reimbursement rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act individual state laws relating pricing sales marketing practices violations laws may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs laws regulations broad scope subject evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws allegations violations could disrupt abbvie 's business result material adverse effect business results operations changes laws regulations may adversely affect abbvie 's business described development manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation changes regulations could affect abbvie various ways example patient protection affordable care act health care education reconciliation act abbvie pays fee related pharmaceuticals sales government programs beginning must record report transfers value physicians teaching hospitals similar reporting requirements enacted state level united states within european union increasing number countries worldwide adopted considering similar laws future legislation regulation markets abbvie serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure legislation regulation could adversely affect abbvie 's business results operations cash flow financial condition prospects abbvie could subject increased monetary penalties andor sanctions including exclusion federal health care programs fails comply terms may resolution department justice 's investigation sales marketing activities depakote may abbott settled us federal state investigations sales marketing activities depakote pleading guilty misdemeanor violation food drug cosmetic act fdca agreeing pay approximately million criminal fines forfeitures approximately million resolve civil claims noncash charge related investigations previously recorded discussed item management 's discussion analysis financial condition results operations plea agreement abbott submitted term probation initially set years shortened years obligations plea agreement transferred become fully binding abbvie conditions probation include certain reporting requirements maintenance certain compliance measures certifications abbvie 's ceo board directors conditions abbvie violates terms probation may face additional monetary sanctions remedies court deems appropriate october court accepted guilty plea imposed agreedupon sentence addition abbott entered fiveyear corporate integrity agreement cia office inspector general us department health human services oig effective date cia october obligations cia transferred become fully binding abbvie cia requires enhancements abbvie 's compliance program fulfillment reporting monitoring obligations management certifications resolutions abbvie 's board directors among requirements abbvie fails comply cia oig may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid abbvie abbott may subject third party claims shareholder lawsuits connection settlement abbvie may required indemnify portion abbott 's costs abbvie 's compliance obligations may resolution department justice 's investigation sales marketing activities depakote impose additional costs burdens abbvie may abbott settled us federal state investigations sales marketing activities depakote pleading guilty misdemeanor violation fdca agreeing pay criminal fines forfeitures civil damages submitting term probation october court accepted guilty plea imposed agreedupon sentence addition abbott entered fiveyear cia oig effective october obligations plea agreement cia transferred become fully binding abbvie compliance requirements settlement impose additional costs burdens abbvie including form employee training third party reviews compliance monitoring reporting obligations management attention international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally sales outside united states make approximately percent abbvie 's net sales risks associated operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action inflation recession fluctuations interest rates compulsory licensing diminished protection intellectual property potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including us foreign corrupt practices act uk bribery act events contemplated risks may individually aggregate material adverse effect abbvie 's revenues profitability deterioration economic position credit quality certain european countries may negatively affect abbvie 's results operations financial instability fiscal deficits certain european countries including greece italy portugal spain may result additional austerity measures reduce costs including health care costs economic conditions continue worsen could result lengthening time reducing collectability abbvie 's outstanding trade receivables increasing government efforts reduce health care spending leading reductions drug prices utilization abbvie 's products ongoing sovereign debt issues countries could increase abbvie 's collection risk given significant amount abbvie 's receivables countries governmental health care systems abbvie may able realize expected benefits investments emerging markets abbvie seeks make investments key emerging markets including brazil china india mexico russia turkey guarantee efforts expand sales markets succeed emerging markets may especially vulnerable periods financial instability may limited resources spend health care abbvie successfully implement emerging markets strategy abbvie must attract retain qualified personnel may required increase reliance thirdparty distributors within certain emerging markets many countries currencies fluctuate substantially currencies devalue abbvie offset devaluations financial performance within countries could adversely affected addition price currency exchange controls limitations participation local enterprises expropriation nationalization governmental actions could affect abbvie 's business results operations emerging markets abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions technology licensing arrangements strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly results operations could adversely affected encounter financial difficulties three wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounted substantially abbvie 's sales united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could negatively impact abbvie 's business results operations changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations abbvie subject evolving complex tax laws may result additional liabilities may affect results operations abbvie subject evolving complex tax laws jurisdictions operates significant judgment required determining abbvie 's tax liabilities abbvie 's tax returns periodically examined various tax authorities although abbott retains risk tax contingencies arising operations preseparation abbvie bears risks future tax contingencies arising operations postseparation due complexity tax contingencies ultimate resolution tax matters related operations postseparation may result payments greater less amounts accrued addition abbvie may impacted changes tax laws including tax rate changes changes laws related treatment remittance foreign earnings new tax laws subsequent interpretations tax law united states jurisdictions abbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors including requiring portion abbvie 's cash flow operations make interest payments debt increasing abbvie 's vulnerability general adverse economic industry conditions reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business limiting abbvie 's flexibility planning reacting changes abbvie 's business industry extent abbvie incurs additional indebtedness risks described could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt terms abbvie 's debt contain covenants restricting financial flexibility number ways including among things restrictions abbvie 's ability ability certain abbvie 's subsidiaries incur mortgages respect principal domestic properties enter sale leaseback transactions respect principal domestic properties restrictions abbvie 's ability merge consolidate entity convey transfer lease abbvie 's properties assets substantially entirety abbvie breaches restrictive covenant indebtedness event default occurs respect indebtedness abbvie 's lenders indebtedness may entitled declare amounts owing respect thereof immediately due payable challenges commercial credit environment may adversely affect abbvie 's future access capital abbvie 's ability issue debt enter financing arrangements acceptable terms could adversely affected material decline demand abbvie 's products solvency customers suppliers significantly unfavorable changes economic conditions volatility world financial markets could increase borrowing costs affect abbvie 's ability access capital markets conditions may adversely affect abbvie 's ability obtain maintain investment grade credit ratings investment abbvie 's cash balance investments marketable securities subject risks may cause losses affect liquidity investments abbvie 's cash currently invested bank deposits money market mutual funds typically hold debt securities issued us federal government highgrade corporate issuers investments abbvie 's future investments may subject credit liquidity market interest rate risks investments suffer market price declines abbvie may recognize earnings decline fair value investments cost basis decline judged temporary risks associated abbvie 's expected cash balance investment portfolio may material adverse effect abbvie 's results operations financial condition abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms may dilutive existing stockholders abbvie may need seek additional financing general corporate purposes example may need increase investment research development activities need funds make acquisitions abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuance equity securities stockholders experience dilution ownership interest abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure systems could adversely affect abbvie 's business abbvie relies sophisticated information technology systems operate business systems potentially vulnerable malicious intrusion random attack loss data privacy breakdown although abbvie invested protection data information technology also monitors systems ongoing basis assurance efforts prevent breakdowns breaches abbvie 's information technology systems could adversely affect abbvie 's business factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's profitability financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards environmental laws differences fair value measurement assets liabilities actual value particularly pensions retiree health care stock compensation intangibles goodwill contingent liabilities litigation absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slowdowns forms labor union activity pressure thirdparty interest groups risks related abbvie 's separation abbott abbvie 's historical financial information necessarily representative results would achieved separate publicly traded company may reliable indicator future results historical information abbvie annual report refers abbvie 's business operated integrated abbott abbvie 's historical financial information derived consolidated financial statements accounting records abbott accordingly financial information included annual report necessarily reflect financial condition results operations cash flows abbvie would achieved separate publicly traded company periods presented abbvie achieve future primarily result factors described prior separation abbvie 's business operated abbott part broader corporate organization rather independent company abbott one affiliates performed various corporate functions abbvie accounting information technology finance abbott currently provides functions abbvie described item certain relationships related transactions director independence abbvie 's historical financial results reflect allocations corporate expenses abbott functions likely less expenses abbvie would incurred operated separate publicly traded company abbvie need make significant investments replicate outsource providers certain facilities systems infrastructure personnel abbvie longer access result separation abbott initiatives develop abbvie 's independent ability operate without access abbott 's existing operational administrative infrastructure costly implement abbvie may able operate business efficiently comparable costs profitability may decline prior separation abbvie able use abbott 's size purchasing power procuring various goods services shared economies scope scale costs employees vendor relationships customer relationships although abbvie entered transition agreements abbott arrangements may fully capture benefits abbvie previously enjoyed result integrated abbott may result abbvie paying higher charges past services separate independent company abbvie may unable obtain goods services prices terms obtained prior separation could decrease abbvie 's overall profitability separate independent company abbvie also may successful negotiating favorable tax treatments credits governmental entities could adverse effect abbvie 's results operations financial condition generally abbvie 's working capital requirements capital general corporate purposes including acquisitions research development capital expenditures historically satisfied part corporatewide cash management policies abbott result separation abbvie may need obtain additional financing banks public offerings private placements debt equity securities strategic relationships arrangements cost capital abbvie 's business may higher abbott 's cost capital prior separation significant changes may occur abbvie 's cost structure management financing business operations result operating company separate abbott additional information past financial performance abbvie 's business basis presentation financial statements abbvie 's business see item management 's discussion analysis financial condition results operations item financial statements supplementary data abbvie builds information technology infrastructure transitions data systems abbvie could incur substantial additional costs experience temporary business interruptions abbvie expects install implement information technology infrastructure support critical business functions including accounting reporting manufacturing process control customer service inventory control distribution abbvie may incur temporary interruptions business operations transition effectively abbott 's existing transactional operational systems data centers transition services support functions abbvie replaces systems abbvie may successful implementing new systems transitioning data may incur substantially higher costs implementation currently anticipated abbvie 's failure avoid operational interruptions implements new systems replaces abbott 's information technology services failure implement new systems replace abbott 's services successfully could disrupt business adversely affect ability collect receivables customers material adverse effect profitability addition abbvie unable replicate transition certain systems ability comply regulatory requirements could impaired abbott may fail perform various transaction agreements executed part separation abbvie may fail necessary systems services place certain transaction agreements expire connection separation abbvie abbott entered separation distribution agreement various agreements including transition services agreements tax sharing agreement international commercial operations agreements finished goods supply agreements contract manufacturing agreements employee matters agreement special products master agreement information technology agreement transitional trademark license agreement agreements discussed greater detail item certain relationships related transactions director independence certain agreements provide performance services company benefit period time abbvie 's separation abbott abbvie relies abbott satisfy performance payment obligations agreements abbott unable satisfy obligations agreements including indemnification obligations abbvie could incur operational difficulties losses addition abbvie abbott entered longterm arrangements special products master agreement relating certain product rights ex us transition services agreement abbott provide abbvie back office functions services certain markets outside united states abbvie established sufficient back office infrastructure conduct operations markets arrangements could lead disputes abbott abbvie abbvie 's rights certain intellectual property territorial commercialization rights allocation costs revenues abbvie 's products operations outside united states abbvie place systems services abbvie agreements providers services transaction longterm agreements terminate abbvie may able operate business effectively profitability may decline abbvie process creating engaging third parties provide systems services replace many systems services abbott currently provides abbvie may successful effectively efficiently implementing systems services transitioning data abbott 's systems abbvie 's systems services may also expensive less efficient systems services abbott expected provide transition period abbvie developing implementing back office functions administrative systems personnel processes markets outside united states abbott initially provide functions assurance abbvie able implement functions effectively without disrupting business markets potential indemnification liabilities abbott pursuant separation agreement could materially adversely affect abbvie separation agreement abbott provides among things principal corporate transactions required effect separation certain conditions separation provisions governing relationship abbvie abbott respect resulting separation description separation agreement see item certain relationships related transactions director independence among things separation agreement provides indemnification obligations designed make abbvie financially responsible substantially liabilities may exist relating business activities whether incurred prior abbvie 's separation abbott well obligations abbott assumed abbvie pursuant separation agreement including relating depakote abbvie required indemnify abbott circumstances set forth separation agreement abbvie may subject substantial liabilities abbvie may able engage certain corporate transactions twoyear period following distribution preserve taxfree treatment abbott separation distribution tax sharing agreement abbvie entered abbott abbvie restricted taking action prevents distribution related transactions taxfree us federal income tax purposes tax sharing agreement twoyear period following distribution abbvie prohibited except certain circumstances entering transaction resulting acquisition percent stock substantially assets whether merger otherwise merging consolidating liquidating issuing equity securities beyond certain thresholds repurchasing capital stock ceasing actively conduct business restrictions may limit abbvie 's ability pursue certain strategic transactions transactions may believe best interests stockholders might increase value business addition tax sharing agreement abbvie required indemnify abbott tax liabilities result acquisition abbvie 's stock assets even participate otherwise facilitate acquisition certain abbvie 's executive officers directors may actual potential conflicts interest previous continuing positions abbott former positions abbott certain executive officers directors abbott common shares options purchase abbott common shares equity awards even though abbvie 's board directors consists majority directors independent abbvie 's executive officers formerly employees abbott ceased employees abbott abbvie executive officers directors continue financial interest abbott common shares addition four abbvie 's directors currently serve board directors abbott continuing ownership abbott common shares equity awards service director companies could create appear create potential conflicts interest abbvie abbott pursue corporate opportunities face decisions could different implications abbvie abbott abbvie may achieve expected benefits separation separation may adversely affect abbvie 's business abbvie may able achieve full strategic financial benefits expected result separation benefits may delayed occur separation distribution expected provide following benefits among others distinct investment identity allowing investors evaluate merits performance future prospects abbvie separately abbott ii efficient allocation capital abbvie iii direct access abbvie capital markets abbvie may achieve anticipated benefits variety reasons including among others abbvie may susceptible market fluctuations adverse events still part abbott b abbvie 's business less diversified abbott 's business prior separation c actions required separate abbott 's abbvie 's respective businesses could diverted management 's attention planning grow operate abbvie 's business created disruptions abbvie 's operations could case impact abbvie 's performance future abbvie fails achieve benefits expected result separation benefits delayed business financial conditions results operations abbvie could adversely affected abbvie may received better terms unaffiliated third parties terms receive agreements abbott agreements abbvie entered abbott connection separation including transition services agreements tax sharing agreement international commercial operations agreements finished goods supply agreements contract manufacturing agreements employee matters agreement special products master agreement information technology agreement transitional trademark license agreement prepared context separation abbvie still whollyowned subsidiary abbott accordingly period terms agreements prepared abbvie independent board directors management team independent abbott result terms agreements may reflect terms would resulted arm'slength negotiations unaffiliated third parties arm'slength negotiations abbott unaffiliated third party another form transaction buyer sale business transaction may resulted favorable terms unaffiliated third party see item certain relationships related transactions director independence risks related abbvie 's common stock abbvie 's stock price may fluctuate significantly abbvie predict prices shares common stock may trade market price abbvie 's common stock may fluctuate significantly due number factors may beyond abbvie 's control including actual anticipated fluctuations abbvie 's operating results changes earnings estimated securities analysts abbvie 's ability meet estimates operating stock price performance comparable companies changes regulatory legal environment abbvie operates domestic worldwide economic conditions addition market price company 's common stock drops significantly stockholders often institute securities class action lawsuits company lawsuit abbvie could cause incur substantial costs could divert time attention management resources abbvie guarantee timing amount payment dividends common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends depend ongoing ability generate cash operations access capital markets abbvie guarantee pay dividend future continue pay dividend abbvie commences paying dividends percentage ownership abbvie may diluted future future percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids making practices bids unacceptably expensive bidder encourage prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting rules regarding stockholders may present proposals nominate directors election stockholder meetings right abbvie 's board issue preferred stock without stockholder approval division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least percent abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition abbvie chosen exempt section delaware general corporation law provision could also delay prevent change control may favor section provides subject limited exceptions persons acquire affiliated person acquires percent outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder percent corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors several agreements abbvie entered abbott require abbott 's consent assignment abbvie rights obligations agreements agreements generally expire within two years abbvie 's separation abbott except certain agreements continue longer terms cases life products covered agreements consent termination rights set forth agreements might discourage delay prevent change control may consider favorable see item certain relationships related transactions director independence detailed description agreements provisions addition acquisition issuance abbvie 's stock could trigger application section e internal revenue code tax sharing agreement abbvie would required indemnify abbott resulting tax indemnity obligation might discourage delay prevent change control may consider favorable cautionary statement regarding forwardlooking statements annual report contains certain forward looking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions among others generally identify forward looking statements speak date statements made matters discussed forward looking statements subject risks uncertainties factors could cause actual results differ materially projected anticipated implied forward looking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake obligation update forwardlooking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois abbvie 's principal manufacturing plants following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts leased property addition abbvie manufacturing facilities united states worldwide abbvie believes facilities suitable provide adequate production capacity united states including puerto rico abbvie owns one distribution center abbvie also four united states research development facilities located abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie 's principal research development facilities located shanghai china ludwigshafen germany except noted principal plants united states listed owned abbvie subsidiaries abbvie remaining manufacturing plants facilities owned leased abbvie subsidiaries abbvie item legal proceedings subject certain exceptions specified separation agreement abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters january except noted abbvie involved various claims legal proceedings investigations including described feasible predict outcome pending claims proceedings investigations certainty management opinion ultimate resolution material adverse effect abbvie 's financial position cash flows results operations several cases pending abbvie generally allege abbott numerous pharmaceutical companies reported false pricing information connection certain drugs reimbursable medicare medicaid cases brought state attorneys general generally seek monetary damages andor injunctive relief attorneys ' fees following cases pending state courts commonwealth kentucky filed september circuit court franklin county kentucky state wisconsin filed june circuit court dane county wisconsin state illinois filed february circuit court cook county illinois state louisiana filed october nineteenth judicial district parish baton rouge louisiana previously reported cases pending abbvie state courts settled previously reported certain federal court cases consolidated pretrial purposes united states district court district massachusetts multi district litigation rules pharmaceutical industry average wholesale price litigation mdl fourth quarter remaining mdl case filed august behalf state south carolina settled dismissed prejudice abbvie seeking enforce patent rights relating testosterone gel drug abbvie sells trademark androgel case filed united states district court district delaware february abbvie alleges perrigo company 's perrigo israel pharmaceutical ltd 's proposed generic product infringes abbvie patent seeks declaratory injunctive relief several pending lawsuits filed unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquired february et al consolidated pretrial purposes united states district court northern district georgia multi district litigation rules androgel antitrust litigation mdl cases brought private plaintiffs federal trade commission ftc generally allege solvay 's patent litigation involving androgel sham litigation patent litigation settlement agreement related agreements three generic companies violate federal state antitrust laws state consumer protection unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees mdl includes three individual plaintiff lawsuits supervalu inc v unimed pharmaceuticals inc et al filed april united states district court northern district georgia rite aid corp et al v unimed pharmaceuticals inc et al walgreen co et al v unimed pharmaceuticals inc et al filed june united states district court middle district pennsylvania subsequently transferred united states district court northern district georgia b seven purported class actions meijer inc et al v unimed pharmaceuticals inc et al rochester drug cooperative inc et al v unimed pharmaceuticals inc et al louisiana wholesale drug co inc et al v unimed pharmaceuticals inc et al filed may united states district court northern district georgia fraternal order police v unimed pharmaceuticals inc et al filed september united states district court northern district georgia jabo 's pharmacy inc v solvay pharmaceuticals inc et al filed october united states district court eastern district tennessee legrand v unimed pharmaceuticals inc et al filed september united states district court northern district georgia health net inc v solvay pharmaceuticals inc filed february northern district georgia c lawsuit brought ftc federal trade commission v watson pharmaceuticals inc et al filed may united states district court northern district georgia february solvay 's motion dismiss cases partially granted ftc 's claims plaintiffs ' claims except alleging sham litigation dismissed may decision affirmed appeal united states court appeals eleventh circuit december united states supreme court approved ftc 's october petition review eleventh circuit 's decision september district court granted summary judgment favor solvay remaining claims private plaintiffs previously reported abbott seeking enforce patent rights relating fenofibrate tablets drug abbvie sells trademark tricor case filed united states district court district new jersey august abbott patent owner laboratoires fournier sa fournier alleged infringement three patents sought injunctive relief mylan pharmaceuticals inc mylan inc mylan related case abbott involved result acquisition fournier laboratories ireland ltd fournier ireland abbott sought enforce additional rights relating fenofibrate tablets case filed united states district court district new jersey august abbott 's subsidiary fournier ireland joint patent owner alkermes pharma ireland limited alkermes alleged infringement two jointlyowned patents sought injunctive relief mylan fourth quarter cases settled dismissed without prejudice abbvie seeking enforce patent rights relating ritonavirlopinavir tablets drug abbvie sells trademark kaletra case filed united states district court northern district illinois march abbvie alleges matrix laboratories inc matrix laboratories ltd mylan inc 's proposed generic products infringe abbvie 's patents seeks declaratory injunctive relief upon matrix 's motion november court granted fiveyear stay litigation unless good cause lift stay shown abbvie seeking enforce patent rights relating ritonavir tablets drug abbvie sells trademark norvir case filed united states district court district delaware april abbvie alleges roxane laboratories inc 's roxane proposed generic product infringes five abbvie patents seeks declaratory injunctive relief also april roxane filed declaratory judgment action united states district court southern district ohio alleging two five abbvie patents invalid infringed roxane 's proposed generic ritonavir product abbvie seeking enforce patent rights relating niacin extended release tablets drug abbvie sells us trademark niaspan case filed united states district court district delaware february abbvie alleges sun pharmaceutical industries ltd 's sun pharma global fze 's generic product infringes abbvie 's patents seeks declaratory injunctive relief second case filed united states district court district delaware june abbvie alleges sandoz inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief third case filed united states district court district delaware january abbvie alleges zydus pharmaceuticals usa inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief fourth case filed united states district court district delaware february abbvie alleges amneal pharmaceutical 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief fifth case filed united states district court district delaware march abbvie alleges mylan inc mylan pharmaceutical inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief sixth case filed united states district court district delaware march abbvie alleges watson laboratories inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief seventh case filed united states district court district delaware june abbvie alleges kremers urban pharmaceuticals inc 's proposed generic product infringes abbvie 's patents seeks declaratory injunctive relief abbvie seeking enforce certain patent rights cover use fully human antitnf alpha antibodies methotrexate treat rheumatoid arthritis case filed united states district court district massachusetts may abbvie alleges centocor ortho biotech inc 's janssen biotech inc 's product simponi infringes abbvie 's patents seeks damages injunctive relief abbvie seeking enforce patent rights relating fenofibric acid capsules drug abbvie sells us trademark trilipix case filed united states district court district new jersey march abbvie subsidiary fournier laboratories ireland ltd allege sandoz inc 's proposed generic product infringes abbvie 's patent seek injunctive relief item mine safety disclosures applicable executive officers registrant following table lists abbvie 's executive officers appointed abbvie corporate officer december name age position richard gonzalez chairman board chief executive officer laura j schumacher executive vice president business development external affairs general counsel william j chase executive vice president chief financial officer carlos alban executive vice president commercial operations john leonard md senior vice president chief scientific officer timothy j richmond senior vice president human resources azita salekigerhardt phd senior vice president operations thomas hurwich vice president controller mr gonzalez abbvie 's chairman chief executive officer served abbott 's executive vice president pharmaceutical products group responsible abbott 's worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbott 's medical technology investment arm mr gonzalez joined abbott held various management positions briefly retiring including abbott 's president chief operating officer president chief operating officer abbott 's medical products group senior vice president president abbott 's former hospital products division hospira inc vice president president abbott 's health systems division divisional vice president general manager abbott 's diagnostics operations united states canada ms schumacher abbvie 's executive vice president business development external affairs general counsel served abbott 's executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel ms schumacher also responsible abbott 's licensing acquisitions function office ethics compliance prior appointment general counsel abbott ms schumacher headed abbott 's litigation department ms schumacher joined abbott mr chase abbvie 's executive vice president chief financial officer served abbott 's vice president licensing acquisitions vice president treasurer divisional vice president controller abbott international mr chase joined abbott mr alban abbvie 's executive vice president commercial operations served abbott 's senior vice president proprietary pharmaceutical products global commercial operations senior vice president international pharmaceuticals vice president pharmaceuticals western europe canada vice president western europe canada vice president european operations mr alban joined abbott dr leonard abbvie 's senior vice president chief scientific officer served abbott 's senior vice president pharmaceuticals research development vice president global pharmaceutical research development dr leonard joined abbott mr richmond abbvie 's senior vice president human resources served abbott 's divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott dr salekigerhardt abbvie 's senior vice president operations served abbott 's vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr salekigerhardt joined abbott mr hurwich abbvie 's vice president controller served abbott 's vice president internal audit divisional vice president controller abbott diagnostics division mr hurwich joined abbott executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange whenissued trading market abbvie 's common stock began nyse december regular way trading abbvie 's common stock began january prior december public market abbvie 's common stock abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges outside united states abbvie 's common stock listed nyse euronext paris six swiss exchange january january highest sales price abbvie 's common stock nyse per share lowest sales price abbvie 's common stock nyse per share shareholders shareholders record abbvie common stock january dividends abbvie expects pay regular cash dividend annual rate per share starting quarterly dividend paid february however timing declaration amount payment dividends abbvie within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends abbvie inc illinois high impact business hib located federal foreign trade subzone subzone dividends may eligible subtraction base income illinois income tax purposes questions please contact tax advisor item selected financial data following table sets forth abbvie 's selected financial information derived unaudited combined financial statements december year ended december ii audited combined financial statements years ended december december historical financial information presented may indicative results operations financial position would obtained abbvie independent company periods shown abbvie 's future performance independent company selected financial information read conjunction combined financial statements accompanying notes management 's discussion analysis financial condition results operations years ended december millions except per share data combined statement earnings data net sales net earnings basic diluted earnings per common share basic diluted average shares outstandinga combined balance sheet data total assets longterm debt lease obligationsb january abbott laboratories distributed million shares abbvie common stock computation basic diluted shares periods december calculated using shares distributed january refer note combined financial statements information regarding earnings per common share b also includes current portion longterm debt lease obligations item management 's discussion analysis financial condition results operations following discussion analysis financial position results operations abbvie inc three years period ended december commentary read conjunction combined financial statements accompanying notes appearing item financial statements supplementary data executive overview company overview abbvie inc abbvie company global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie products used treat rheumatoid arthritis psoriasis crohn 's disease hiv cystic fibrosis complications low testosterone thyroid disease parkinson 's disease ulcerative colitis complications associated chronic kidney disease among indications abbvie also pipeline promising new medicines including compounds indications phase ii phase iii development across important medical specialties immunology renal care hepatitis c virus hcv women 's health oncology neuroscience including multiple sclerosis alzheimer 's disease abbvie approximately employees products sold countries abbvie operates one business segment pharmaceutical products january abbvie became independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbott shareholder record close business december received one share abbvie common stock abbott common share held record date abbvie incorporated delaware april comprised abbott 's former researchbased pharmaceuticals business abbvie 's registration statement form declared effective us securities exchange commission december abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january refer basis presentation section information abbvie 's products include broad line adult pediatric pharmaceuticals manufactured marketed sold worldwide generally sold directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers distribution centers public warehouses outside united states sales made either directly customers distributors depending market served certain products co marketed copromoted companies humira 's worldwide sales increased billion compared billion billion abbvie began worldwide launch humira rheumatoid arthritis followed launches six additional indications united states eight additional indications european union humira received approval treatment moderately severely active ulcerative colitis adult patients inadequate response conventional therapy european commission april us food drug administration fda october july humira received approval european commission treatment severe axial spondyloarthritis adult patients xray evidence structural damage november received approval european commission treatment pediatric patients aged years severe active crohn 's disease failed intolerant contraindications conventional therapy abbvie studying additional indications humira substantial research development selling support continues dedicated maximizing worldwide potential humira abbvie forecasts low doubledigit growth worldwide humira sales acquisition solvay sa 's us pharmaceuticals business solvay certain product rights billion february added several new products including rights androgel creon abbvie 's portfolio generic competition began november tricor expected begin second half niaspan second half early trilipix result sales abbvie 's combined lipid franchise including tricor trilipix niaspan simcor billion billion expected total less billion decrease sales zemplar million million reflects impact changes reimbursement regulations resulting health care reform legislation austerity measures implemented several european countries reduced health care spending affected pharmaceuticals pricing countries years presented strategic objectives abbvie 's longterm strategy maximize existing portfolio new indications share gains increased reach geographic expansion underserved markets also advancing new product pipeline successfully execute longterm strategy abbvie focus expanding humira sales advancing pipeline expanding presence emerging markets managing product portfolio maximize value abbvie expects continue drive strong humira sales growth several ways abbvie seeks expand humira patient base applying regulatory approval new indications humira treating conditions axial peripheral spondyloarthritis uveitis abbvie also seek drive humira sales growth expanding market share presence underserved markets research development rd efforts continue focus significant portion expenditures compounds immunology oncology neuroscience pain management virology renal disease women 's health abbvie 's goal bring market products demonstrate strong clinical performance patients economic value payors current research development projects described research development section abbvie plans continue making investments key emerging markets including brazil china mexico russia continued penetration humira leading products expected help drive growth markets abbvie continue investment products durable sales making adjustments necessary increase value product portfolio abbvie plans achieve objective variety ways depending product circumstances example identifying supply chain efficiencies pursuing additional indications optimizing residual value products reach end exclusivity abbvie believes approach allow company maintain strong operating margin research development rd innovation scientific productivity continue key strategic priority abbvie abbvie 's longterm success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie pipeline compounds indications phase ii iii development individually collaboration license agreements rd focused therapeutic areas include virology renal disease neuroscience oncology immunology women 's health among others virology abbvie released positive phase ii phase iib results interferonfree studies treatment hcv october abbvie initiated comprehensive phase iii program genotype hcv involves combinations abt protease inhibitor hcv infection abt polymerase inhibitor abt nsa inhibitor renal disease abbvie 's renal care pipeline includes atrasentan treatment diabetic chronic kidney disease ckd phase iib study atrasentan patients diabetic kidney disease began june completed results presented atrasentan potentially first compound launched treat diabetic nephropathy specifically targeting albuminuria slowing progression ckd abbvie also investigating abt phase iib development treatment acute kidney injury associated major surgeries abbvie entered agreement reata pharmaceuticals inc reata exus rights excluding certain asian markets bardoxolone methyl investigational treatment ckd global phase iii clinical trial initiated june october reata informed abbvie discontinuing phase iii clinical study discontinuation based recommendation study 's independent data monitoring committee regarding safety concerns due excess serious adverse events mortality bardoxolone methyl arm reata abbvie closely examine data study determine whether appropriate path forward development bardoxolone methyl ckd indications neuroscience pain abbvie clinical studies underway multiple compounds target receptors brain help regulate mood memory neurological functions conditions including schizophrenia pain alzheimer 's disease multiple sclerosis ms abbvie collaborating biogen idec develop daclizumab treatment relapsing remitting form ms common form affects nearly percent newly diagnosed ms patients daclizumab anticd monoclonal antibody currently phase iii development abbvie investigating abt annr modulator alzheimer 's disease cognitive deficits schizophrenia additional phase iib studies began march development abt treatment multiple pain indications suspended based upon fda classwide feedback levodopacarbidopa intestinal gel completed phase iii program abbvie pursuing regulatory approval united states product sold duodopa name outside united states oncology abbvie focused development targeted treatments inhibit tumor growth improve response common cancer therapies abbvie 's oncology pipeline includes following elotuzumab anticd antibody treatment multiple myeloma collaboration bristolmyers squibb phase iii development began june veliparib parpinhibitor phase iib study brcamutated breast cancer treated chemotherapy initiated veliparib also phase ii evaluation treatment variety solid tumors including brain metastases nonsmallcell lung cancer treated radiation therapy non smallcell lung cancer combination chemotherapy abt nextgeneration bcl inhibitor development chronic lymphocytic leukemia expected start phase iii evaluation molecular targets explored antibodydrug conjugate approaches linking antitarget antibodies potent cytotoxic agents women 's health abbvie developing novel oral gonadotropinreleasing hormone gnrh antagonist elagolix collaboration neurocrine biosciences treatment endometriosisrelated pain uterine fibroids phase iii study endometriosis began mid phase iia study uterine fibroids initiated november immunology abbvie developing several additional indications humira number nextgeneration programs underway address immunemediated conditions including following dual variable domain immunoglobulin dvdig technology represents approach target multiple diseasecausing antigens single biologic agent proprietary technology could lead nextgeneration biologic treatments complex conditions cancer rheumatoid arthritis multiple pathways involved disease abbvie collaborating biotest ag anticd biologic known tregalizumab compound currently phase iib clinical trials rheumatoid arthritis psoriasis glpg nextgeneration oral janus kinase jak inhibitor developed galapagos nv collaboration entered first quarter glpg currently phase iib development treat rheumatoid arthritis may able address autoimmune diseases fourth quarter abbvie entered collaboration reata joint development commercialization secondgeneration oral antioxidant inflammation modulators additional indications formulations abbvie continues dedicate rd efforts expanding indications humira including fields rheumatology peripheral spondyloarthritis axial spondyloarthritis pediatric enthesitis related arthritis gastroenterology pediatric crohn 's disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase iii trials ongoing preparation regulatory applications uveitis united states european union peripheral axial spondyloarthritis united states peripheral spondyloarthritis european union hidradenitis suppurativa united states european union following registrations approvals occurred since january european union approval pediatric crohn 's disease obtained november ulcerative colitis european union approval obtained april approval united states obtained september axial spondyloarthritis approval european union obtained july registration submission made united states november new formulations abbvie 's existing pharmaceutical products approved including month month strengths lupron depot united states june august respectively united states new strength creon approved june androgel approved april additional registration submission new strength creon made september given numerous sources potential future growth individual project expected material cash flows results operations next five years factors considered included rd expenses projected incurred project next year relative abbvie 's total rd expenses well qualitative factors marketplace perceptions impact new product abbvie 's overall market position delays abbvie 's rd activities expected material impact operations aggregate cost complete numerous pharmaceutical projects currently development expected material total cost complete depend upon abbvie 's ability successfully complete project rate project advances nature extent costsharing arrangements ultimate timing completion given potential significant delays high rate failure inherent research development new pharmaceutical products possible accurately estimate total cost complete projects currently development however abbvie plans continue manage portfolio projects achieve research development spend equal approximately percent net sales year abbvie regularly accumulate make management decisions based total expenses incurred particular development phase given period basis presentation abbvie 's historical combined financial statements prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceuticals business abbott part abbvie periods presented combined financial statements reflect abbvie 's financial position results operations cash flows business operated part abbott prior distribution conformity us generally accepted accounting principles combined financial statements principally represent historical results operations assets liabilities abbott 's proprietary pharmaceutical products segment historical financial statements included allocation certain assets liabilities historically held abbott corporate level specifically identifiable allocable abbvie prior cash equivalents shortterm investments restricted funds held abbott allocated abbvie unless cash investments held entity transferred abbvie december cash equivalents shortterm investments reflected abbvie 's direct ownership assets prior longterm debt shortterm borrowings allocated abbvie none debt recorded abbott directly attributable guaranteed abbvie abbvie issued billion longterm debt maturities ranging three years billion commercial paper reflected abbvie 's combined balance sheet december intracompany abbvie transactions eliminated december intercompany transactions abbvie abbott considered effectively settled combined financial statements time transactions recorded total net effect settlement intercompany transactions reflected combined statements cash flow financing activity combined balance sheets net parent company investment abbvie december outstanding intercompany transactions abbvie abbott reflected due abbott laboratories due abbott laboratories combined balance sheet abbvie 's historical financial statements included allocation expenses related certain abbott corporate functions including senior management legal human resources finance information technology quality assurance expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable reflection utilization services provided benefit received company periods presented allocations may however reflect expense company would incurred independent publiclytraded company periods presented subsequent separation abbvie expects incur additional costs associated independent publiclytraded company primarily higher charges past abbott various services continue provided transition basis newly established expanded corporate functions abbvie expects incur onetime costs primarily establish certain standalone abbvie functions information technology systems establish infrastructure outside united states complete separation certain countries portion expenditures capitalized depreciated assets ' useful lives remainder expensed incurred depending nature cost abbvie believes cash flows operations sufficient fund additional corporate expenses historical financial statements necessarily include expenses would incurred abbvie separate standalone entity may necessarily reflect abbvie 's results operations financial position cash flows abbvie standalone company periods presented refer note description transactions abbvie abbott results operations net sales percent change actual constant currency currency rates rates years ended millions united states international net sales increase sales primarily due higher humira sales partially offset impact unfavorable foreign currency entry generic tricor fourth quarter following table details sales key products percent change actual constant currency currency rates rates years ended december millions humira united states international total androgel united states tricortrilipix united states kaletra united states international total niaspan united states synagis united states international total lupron united states international total sevoflurane united states international total synthroid united states norvir united states international total zemplar united states international total creon united states total comparisons presented constant currency rates reflect comparative local currency sales prior year 's foreign exchange rates measure provides information change net sales assuming foreign currency exchange rates changed prior current period abbvie believes nongaap measure change net sales constant currency rates used conjunction gaap measure change net sales actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another increase humira sales reflects market growth higher market share across various countries well higher pricing certain geographies humira received approval european commission april fda october treatment moderately severely active ulcerative colitis adult patients inadequate response conventional therapy approval european commission humira became first selfinjectable biologic therapy treatment moderately severely active ulcerative colitis adults july humira received approval european commission treatment severe axial spondyloarthritis adult patients xray evidence structural damage november humira received approval european commission treatment pediatric patients aged years severe active crohn 's disease failed intolerant contraindications conventional therapy approval marked ninth indication humira european union decline tricor trilipix niaspan sales reflects softness overall branded cholesterol market introduction generic version tricor united states market november result sales abbvie 's combined lipid franchise including tricor trilipix niaspan declined percent compared license agreement trilipix mg mg generic competition may begin january except certain circumstances license may commence early july agreement relating abbvie 's niacin products acquired kos pharmaceuticals acquisition niaspan may become subject generic competition september decline kaletra revenues primarily due lower market share various countries due impact competition increase androgel sales reflected higher prices market share gains launch androgel second quarter volume growth us testosterone replacement market androgel holds number one market share position androgel sales expected impacted generic competition sales sevoflurane impacted generic competition sales zemplar impacted changes reimbursement regulations resulting health care reform legislation gross margin percent change years ended december millions gross margin net sales increase gross profit margin primarily due product mix improved efficiencies higher prices certain geographies favorable impact foreign currency partially offset pricing pressures various markets improvement also reflects lower amortization expense intangible assets impact restructuring programs implemented realign various manufacturing operations changes various governmental rebate programs continue negative effect gross profit margins health care reform legislation united states resulted increased additional medicaid rebates beginning additional rebates related medicare part donut hole beginning negatively affected abbvie 's business negative impact rebates resulting health care reform legislation grew million approximately million selling general administrative percent change years ended december millions selling general administrative net sales selling general administrative sga expenses included million costs associated separation abbvie abbott sga expenses included litigation charges million billion respectively related depakote investigation sga expenses included million million respectively related restructuring integration projects associated acquisition solvay refer note information depakote charge note information solvay acquisition excluding separation costs litigation charges solvayrelated restructuring integration costs years sga expenses increased percent percent percent respectively increases sga expenses threeyear period due primarily increased selling marketing support new existing products including continued spending humira impact pharmaceutical fee imposed us health care reform legislation research development acquired inprocess research development percent change years ended december millions research development net sales acquired inprocess research development rd increased reflecting continued pipeline spending programs biologics neuroscience virology well million rd milestone payment related product development treatment chronic kidney disease rd expenses also included restructuring charges million million acquired inprocess research development iprd expense included charge million acquisition abt charge million result entering global collaboration develop commercialize oral nextgeneration jak inhibitor charge million result entering twoyear collaboration agreement research develop commercialize three compounds antibodydrug conjugate approaches iprd expenses included charge million achievement developmental milestone licensing agreement treatment ckd charges million million entering collaboration agreements secondgeneration oral antioxidant inflammation modulators anticd biologic treatment rheumatoid arthritis psoriasis respectively iprd expenses included charges million million result entering licensing agreement treatment ckd entering collaboration agreement treatment endometriosis respectively interest expense interest expense net million comprised primarily interest expense outstanding debt bridge facility fees related separation abbott partially offset interest income november abbvie issued billion longterm debt maturities ranging three years abbvie entered interest rate swaps various financial institutions converted billion fixed rate interest rate debt floating interest rate debt addition abbvie issued billion commercial paper fourth quarter abbvie expects incur approximately million net interest expense income expense income expense net included income million resolution contractual agreement loss million impairment equity security income expense net included losses million million fair value adjustments accretion contingent consideration related acquisition solvay income expense net also included ongoing contractual payments takeda associated conclusion tap pharmaceutical products inc joint venture income tax expense income tax rates percent percent percent income taxes included recognition tax benefits totaling approximately million million respectively result favorable resolutions various tax positions pertaining prior years income taxes also reflected nondeductibility litigation reserve excluding discrete items effective tax rates less statutory federal income tax rate percent principally due benefit lower statutory tax rates tax exemptions puerto rico foreign taxing jurisdictions reduced tax rates percentage points respectively abbvie expects effective income tax rate approximately percent excluding discrete items october puerto rico enacted legislation assesses excise tax beginning certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold majority tax creditable us income tax purposes excise tax totaled approximately million million respectively transition abbott cost operate independent company combined financial statements reflect operating results financial position abbvie operated abbott rather independent company abbvie incur additional ongoing operating expenses operate independent company costs include cost various corporate headquarters functions incremental information technologyrelated costs incremental costs operate standalone back office infrastructure outside united states order establish standalone functions abbvie also incur nonrecurring expenses capital expenditures transition services agreement united states covers certain corporate support services abbvie historically received abbott services include information technology accounts payable payroll financial functions well engineering support various facilities quality assurance support administrative services term service agreement varies activity agreement facilitates separation allowing abbvie operate independently prior establishing standalone back office systems across organization operating costs various information technology systems maintained abbott allocated abbvie bases management believes reasonable included allocations abbvie 's proportionate share fixed operating costs independent company abbvie 's information technology operating costs may higher costs allocated historical combined financial statements addition abbvie incur nonrecurring expenses capital expenditures establish independent information technology systems markets outside united states abbvie currently sufficient back office infrastructure operate without transition service agreements abbott abbott entered transition services agreement abbvie provide services outside united states including back office services certain countries two years separation back office services provided include information technology accounts payable payroll receivables collection treasury financial functions well order entry warehousing administrative services transition services agreement allows abbvie operate international pharmaceuticals business independently prior establishing standalone back office infrastructure countries transition abbott abbvie incur nonrecurring expenses expand international infrastructure addition certain international markets marketing authorizations sell abbvie 's products continue held abbott postseparation authorizations transferred applicable regulatory channels practicable estimate costs would incurred periods presented historical financial statements functions described actual costs would incurred abbvie operated standalone company periods would depended various factors including organizational design outsourcing strategic decisions related corporate functions information technology international back office infrastructure financial position liquidity capital resources years ended december millions cash flows provided byused operating activities investing activities financing activities strong cash flows operating activities three years driven higher net earnings focused working capital management abbvie recorded noncash charges billion accrued liabilities accrue litigation reserve related claims abbvie 's previous sales marketing activities depakote abbvie made payments billion settle claims abbvie issued senior notes billion november billion commercial paper december abbott 's guarantee senior notes terminated upon distribution abbvie common stock shareholders abbott upon separation january senior notes maturities ranging three years may redeemed time except floating rate notes senior notes series redemption price equal principal amount plus makewhole premium balance commercial paper outstanding december billion weighted average interest rate abbvie may retire issue additional commercial paper meet liquidity requirements needed historically cash flows financing activities represented cash transactions abbott company 's cash equivalents shortterm investments increased million december million december abbott contributed approximately billion cash newly formed abbvie entities abbvie distributed billion cash debt securities abbott subsequent separation effective january abbvie longer participates cash management funding arrangements abbott significant portion cash equivalents december considered reinvested indefinitely foreign subsidiaries abbvie expect reinvestment affect liquidity capital resources funds needed operations united states abbvie would required accrue pay us income taxes repatriate funds abbvie believes sufficient sources liquidity support assumption disclosed amount undistributed earnings december considered reinvested indefinitely february company announced billion stock repurchase program effective immediately purchases abbvie shares may made time time management 's discretion plan time limit discontinued time dividend per share paid february stockholders record january board directors declared quarterly cash dividend per share stockholders record april payable may abbvie expects pay regular cash dividend annual rate per share however timing declaration amount payment dividends within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors substantially abbvie 's trade receivables greece portugal italy spain governmental health systems global economic conditions liquidity issues countries resulted may continue result delays collection receivables credit losses time collect outstanding receivables increased however exception greece collection times improved relative amounts one year past due decreased relative outstanding net governmental receivables countries december follows net receivables one year net receivables past due millions greece portugal italy spain total exception greece abbvie historically collected almost outstanding receivables countries abbvie continues monitor creditworthiness customers located geographic areas establishes allowance accounts receivable probable collected addition closely monitoring economic conditions budgetary fiscal developments countries abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie also monitors potential periodically utilized factoring arrangements mitigate credit risk although receivables included arrangements historically material amount total outstanding receivables government funding become unavailable countries significant adverse changes reimbursement practices occur abbvie may able collect entire balance credit facility access capital credit ratings credit facility abbvie currently billion unsecured fiveyear revolving credit facility syndicate lenders entered july also supports commercial paper borrowings date separation january abbott 's obligations facility relieved abbvie became sole obligor credit facility enables company borrow funds floating interest rates december company compliance credit facility covenants commitment fees new credit facility material amounts outstanding credit facility december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations issuing additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives credit ratings late october moody 's investor service standard poor 's corporate assigned ratings baa respectively abbvie unfavorable changes ratings may adverse impact future financing arrangements however would affect company 's ability draw credit facility would result acceleration scheduled maturities company 's outstanding debt contractual obligations following table summarizes abbvie 's estimated contractual obligations december less one three millions total one year three years five years five years shortterm borrowings longterm debt capital lease obligations including current maturities interest longterm debta purchase obligations otherb longterm liabilitiesc total includes estimated future interest payments longterm debt securities interest payments debt calculated future periods using interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december refer notes discussion regarding company 's debt instruments related interest rate agreements outstanding december b includes company 's significant unconditional purchase obligations commitments exceed company 's projected requirements made normal course business c excludes pension postemployment benefits related deferred compensation cash outflows timing funding uncertain dependent future movements interest rates investment returns changes laws regulations variables included amount components longterm liabilities including restructuring expected payment related contingent sales based payment recognized part acquisition solvay refer notes information abbvie enters rd collaboration arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements material one annual reporting period however milestones multiple products covered arrangements would happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement result potential payments included table contractual obligations refer note discussion collaboration arrangements critical accounting policies preparation financial statements accordance us generally accepted accounting principles requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer rebates abbvie provides rebates pharmacy benefit management companies state agencies administer federal medicaid program insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate amounts usually based upon volume purchases using contractual statutory prices product type rebate factors used calculations accrual rebate include identification products sold subject rebate customer government agency price terms apply rebate estimated lag time sale payment rebate using historical trends rebate adjusted current changes abbvie estimates amount rebate paid records liability reduction gross sales abbvie records sale product settlement rebate generally occurs two eight months sale abbvie regularly analyzes historical rebate trends makes adjustments reserves changes trends terms rebate programs rebate chargeback accruals recorded period related sales reflected reduction sales rebates chargebacks totaled billion billion billion respectively percent percent percent respectively gross sales subject rebate onepercentage point increase percentage rebates related gross sales would decrease net sales million abbvie considers one percentage point increase reasonably likely increase percentage rebates related gross sales allowances cash discounts returns charged gross sales million million million respectively management analyzes adequacy ending rebate accrual balances quarter united states significant charges gross sales medicaid medicare rebates pharmacy benefit manager rebates wholesaler chargebacks medicaid rebates relate federal medicaid program administered state agencies whereby rebates provided participating state local government entities various laws regulations cases supplemental rebates also provided states contractual agreements medicare rebates negotiated managed care organizations manage prescription drug plans covering medicare part drug benefit pharmacy benefit manager rebates arise contractual agreements private health care plans seek reduce costs negotiating discounts pharmaceuticals manufacturers wholesaler chargeback programs wholesaler charges abbvie back difference price paid wholesaler abbvie price paid end customer wholesaler contractual discount agreements negotiated abbvie end customer order evaluate adequacy ending accrual balances type rebate management uses internal external data estimate level inventory distribution channel rebate claims processing lag time rebate external data sources used estimate inventory distribution channel include inventory levels periodically reported wholesalers management estimates processing lag time based periodic sampling claims data estimate price rebate percentage systems calculations used track sales product customer estimate contractual statutory price abbvie 's systems calculations developed time rebates become significant abbvie believes reliable following table analysis three largest rebate accruals chargeback allowances comprise approximately percent combined rebate provisions charged revenues remaining rebate provisions charged gross sales significant determination operating earnings medicaid pharmacy benefit medicare manager wholesaler millions rebates rebates chargebacks balance january provisions payments balance december provisions payments balance december provisions payments balance december historically adjustments prior years ' rebate accruals material net income abbvie employs various techniques verify accuracy claims submitted possible works organizations submitting claims gain insight changes might affect rebate amounts medicaid medicare government agency programs calculation rebate involves interpretations relevant regulations subject challenge change interpretation cash discounts returns cash discounts reliably estimated product returns reliably estimated abbvie 's historical returns low sales return terms sales terms remained relatively unchanged several periods pension postemployment benefits abbvie employees participate various pension postemployment health care plans sponsored abbott abbvie 's financial statements plans accounted multiemployer benefit plans liabilities reflected abbvie 's combined balance sheets unfunded contributions due end reporting period effective january connection separation abbvie abbott abbvie record net benefit plan obligations transferred abbott abbvie 's combined statements earnings included expense allocations benefits expenses funded intercompany transactions abbott reflected within net parent company investment abbvie certain pension plans germany puerto rico canada ireland united kingdom united states direct obligations abbvie recorded combined financial statements december abbvie engages outside actuaries assist determination obligations costs plans valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates discount rate selected based current market rates highquality fixedincome investments december year expected longterm rate return based asset allocation historical performance current view expected future returns health care cost trend rate selected reviewing historical trends current views projected future health care cost increases significant assumptions used determining calculations disclosed note combined financial statements income taxes abbvie 's combined financial statements income tax expense deferred tax balances calculated separate tax return basis although abbvie 's operations historically included tax returns filed respective abbott entities abbvie business part future stand alone company abbvie file tax returns behalf deferred taxes effective tax rate may differ historical periods abbvie abbott entered tax sharing agreement effective date separation january tax contingencies prior separation abbott indemnify hold abbvie harmless tax positions settled amounts excess recorded liabilities abbvie benefit prior tax positions resolved favorably recorded amounts litigation company subject contingencies legal proceedings claims arise normal course business refer note information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected significant litigation reserves december valuation intangible assets goodwill abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur frequency companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets relate iprd reviewed impairment annually event could result impairment occurs refer note combined financial statements information impairment reviews company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views company similar companies use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates december goodwill intangible assets totaled million million respectively amortization expense intangible assets million million million respectively impairments goodwill results last impairment test indicated fair value reporting unit substantially excess carrying value abbvie recorded impairment charges million million respectively certain projects development certain regulatory matters legislative issues first quarter patient protection affordable care act health care education reconciliation act collectively referred herein health care reform legislation signed law united states health care reform legislation included increase basic medicaid rebate rate percent percent extended rebate drugs provided medicaid managed care organizations starting additional rebates incurred related medicare part coverage gap donut hole medicare medicaid rebate changes continue negative effect abbvie 's gross profit margin future years abbvie began recording annual fee imposed health care reform legislation companies sell branded prescription drugs specified government programs amount annual fee totaled approximately million based ratio certain abbvie 's sales compared total sales covered entities multiplied fixed dollar amount specified legislation year fee tax deductible included sga expenses abbvie 's markets highly competitive subject substantial government regulations abbvie expects debate continue availability method delivery payment health care products services possible predict extent abbvie health care industry general might adversely affected factors future complete discussion factors contained item business item risk factors item quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures refer note information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency translation exposures euro british pound japanese yen canadian dollar various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts designated cash flow hedges variability cash flows due changes foreign currency exchange rates markedtomarket resulting gains losses reflected accumulated comprehensive income loss deferred gains losses contracts included cost products sold time products sold third party generally within twelve months december abbvie held billion million respectively contracts mature following calendar year abbvie enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables contracts designated hedges markedtomarket resulting gains losses reflected income generally offset losses gains foreign currency exposure managed december abbvie held billion billion respectively foreign currency forward exchange contracts following table reflects total foreign currency forward contracts outstanding december fair fair weighted carrying weighted carrying average value average value contract exchange receivable contract exchange receivable millions amount rate payable amount rate payable receive primarily us dollars exchange following currencies euro british pound japanese yen canadian dollar currencies na na total company estimates percent appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contacts percent appreciation believed reasonably possible nearterm change foreign currencies currency restrictions enacted venezuela require abbvie obtain approval venezuelan government exchange venezuelan bolivars us dollars require exchange made official exchange rate established government effective february venezuelan government devalued official exchange rate expected material impact financial results company interest rate risk interest rate swaps used manage company 's exposure changes interest rates fixedrate debt effect hedges change fixed interest rate variable rate abbvie use derivative instruments interest rate swaps manage exposure changes interest rates investment securities december abbvie interest rate hedge contracts totaling billion company estimates increase interest rates basis points would decrease fair value interest rate swap contracts approximately million realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt million basis point change believed reasonably possible nearterm change rates market price sensitive investments abbvie holds availableforsale equity securities strategic technology acquisitions market value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses income temporary decline value occurs hypothetical percent decrease share prices investments would immaterial decrease fair value december percent decrease believed reasonably possible nearterm change share prices nonpublicly traded equity securities abbvie holds equity securities strategic technology acquisitions traded public stock exchanges carrying value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses income temporary decline estimated value occurs item financial statements supplementary data combined financial statements combined statements earnings combined statements comprehensive income combined statements cash flows combined balance sheets combined statements parent company equity notes combined financial statements report independent registered public accounting firm abbvie inc subsidiaries combined statements earnings years ended december millions except per share data net sales cost products sold selling general administrative research development acquired inprocess research development total operating costs expenses operating earnings interest expense net net foreign exchange gain loss income expense net earnings income tax income tax expense net earnings per share data basic diluted earnings per sharea january abbott laboratories distributed million shares abbvie common stock computation basic diluted earnings per common share periods december calculated using shares distributed january accompanying notes integral part combined financial statements abbvie inc subsidiaries combined statements comprehensive income years ended december millions net earnings foreign currency translation gain loss adjustments pension postemployment benefits net tax benefit unrealized loss gains marketable equity securities net tax benefit expense hedging activities net tax benefit expense comprehensive loss comprehensive income accompanying notes integral part combined financial statements abbvie inc subsidiaries combined statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile earnings net cash operating activities depreciation amortization intangible assets stockbased compensation acquired inprocess research development changes operating assets liabilities net acquisitions accounts receivable inventories prepaid expenses assets accounts payable liabilities cash flows operating activities cash flows investing activities acquisitions investments net cash acquired acquisitions property equipment release deposit restricted funds purchases investment securities sales investment securities cash flows investing activities cash flows financing activities proceeds issuance longterm debt net change shortterm borrowings net transactions abbott laboratories excluding noncash items cash flows financing activities effect exchange rate changes cash equivalents net increase cash equivalents cash equivalents beginning year cash equivalents end year accompanying notes integral part combined financial statements abbvie inc subsidiaries combined balance sheets december millions assets current assets cash equivalents shortterm investments accounts receivable due abbott laboratories inventories deferred income taxes prepaid expenses total current assets investments net property equipment intangible assets net amortization goodwill assets total assets liabilities net parent company investment abbvie inc current liabilities shortterm borrowings current maturities longterm debt lease obligations accounts payable accrued liabilities due abbott laboratories total current liabilities longterm liabilities longterm debt lease obligations commitments contingencies parent company equity net parent company investment abbvie inc accumulated comprehensive loss total parent company equity total liabilities net parent company investment abbvie inc accompanying notes integral part combined financial statements abbvie inc subsidiaries combined statements parent company equity net parent accumulated company comprehensive years ended december millions investment income total balance january net earnings net transactions abbott laboratories comprehensive loss balance december net earnings net transactions abbott laboratories comprehensive loss balance december net earnings net transactions abbott laboratories assumption accumulated unrealized losses pension post employment benefits net tax benefit comprehensive loss balance december accompanying notes integral part combined financial statements abbvie inc subsidiaries notes combined financial statements note basis presentation principal business abbvie inc abbvie company discovery development manufacture sale broad line proprietary pharmaceutical products substantially abbvie 's us sales three wholesalers outside united states products sold primarily health care providers distributors depending market served january abbvie became independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbvie incorporated delaware april abbott 's board directors approved distribution shares abbvie november abbvie 's registration statement form declared effective us securities exchange commission december january abbott 's shareholders record close business december received one share abbvie common stock every one share abbott 's common stock held record date abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january accompanying combined financial statements prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceutical business abbott part abbvie periods presented combined financial statements reflected abbvie 's financial position results operations cash flows business operated part abbott prior distribution conformity us generally accepted accounting principles combined financial statements included allocation certain assets liabilities historically held abbott corporate level specifically identifiable allocable abbvie prior cash equivalents shortterm investments restricted funds held abbott allocated abbvie unless assets held entity transferred abbvie december abbvie 's combined balance sheet reflected direct holdings abbvie legal entities intracompany transactions accounts eliminated prior intercompany transactions abbvie abbott considered effectively settled combined financial statements time transaction recorded result total net effect settlement intercompany transactions reflected combined statements cash flows financing activity combined balance sheet net parent company investment abbvie december outstanding intercompany transactions abbvie abbott reflected due abbott laboratories due abbott laboratories combined balance sheet abbvie 's combined financial statements included allocation expenses related certain abbott corporate functions including senior management legal human resources finance information technology quality assurance expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable periods presented however allocations may indicative actual expenses would incurred abbvie operated independent publiclytraded company periods presented abbvie employees participated various benefit stockbased compensation programs maintained abbott portion cost programs included abbvie 's financial statements however abbvie 's combined balance sheet include equity related stockbased compensation plans see note note description accounting postemployment benefits stockbased compensation respectively note summary significant accounting policies use estimates financial statements prepared accordance generally accepted accounting principles united states necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts sales rebates income taxes pension postemployment benefits valuation intangible assets goodwill litigation financial instruments inventory accounts receivable exposures revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer provisions discounts rebates sales incentives customers returns adjustments provided period related sales recorded sales incentives customers material historical data readily available reliable used estimating amount reduction gross sales revenue launch new product improved version existing product shipments excess customer 's normal requirements recorded conditions noted met situations management records returns reserve revenue necessary sales product rights marketable products recorded revenue upon disposition rights research development costs internal research development rd costs expensed incurred clinical trial costs incurred third parties expensed contracted work performed contingent milestone payments due third parties research development collaborations precommercialization milestones milestone payment obligations expensed milestone results achieved payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangible assets net accumulated amortization advertising costs associated advertising expensed year incurred included selling general administrative expenses sga advertising expenses million million million respectively pension postemployment benefits abbvie records annual expenses relating pension benefit postemployment plans based calculations include various actuarial assumptions including discount rates assumed asset rates return compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial losses gains amortized remaining service attribution periods employees corridor method accordance rules accounting postemployment benefits differences expected longterm return plan assets actual annual return amortized fiveyear period abbvie employees participate defined benefit pension postemployment plans sponsored abbott include participants abbott 's businesses plans accounted multiemployer plans historical financial statements abbvie result asset liability recorded abbvie historical combined balance sheets recognize funded status plans subsequent separation abbott abbvie 's portion defined benefit pension plans separated abbott defined benefit pension plans time funded status plan reflected abbvie combined balance sheets using december measurement date addition participation defined benefit pension post employment plans sponsored abbott abbvie sole sponsor certain defined benefit pension postemployment plans funded status plans recorded combined balance sheets abbvie december refer note information regarding abbvie 's pension postemployment plans income taxes income taxes earnings reflect annual effective rates including charges interest penalties deferred income taxes provided tax effect temporary differences tax bases assets liabilities reported amounts financial statements based enacted tax laws rates combined balance sheet december appropriately revised increase deferred tax liabilities longterm liabilities million decrease deferred tax assets assets million decrease net parent company investment abbvie million properly reflect temporary differences attributable abbvie assets abbvie 's combined financial statements income tax expense deferred tax balances calculated separate tax return basis although abbvie 's operations historically included tax returns filed respective abbott entities abbvie business part future stand alone entity abbvie file tax returns behalf deferred taxes effective tax rate may differ historical periods abbvie maintain income taxes payable tofrom account abbott exception certain entities outside united states transferred abbvie separation abbvie deemed settled current tax balances abbott tax paying entities respective jurisdictions settlements reflected changes net parent company investment cash equivalents cash equivalents include time deposits money market funds original maturities three months less investments shortterm investments consist primarily time deposits us treasury securities carried fair value investments marketable equity securities classified availableforsale recorded fair value unrealized holding gains losses net tax included accumulated comprehensive income loss investments equity securities traded public stock exchanges heldtomaturity debt securities recorded cost abbvie reviews carrying value investments quarter determine whether temporary decline market value exists abbvie considers factors affecting investee factors affecting industry investee operates general equity market trends company considers length time investment 's market value cost nearterm prospects recovery abbvie determines temporary decline occurred cost basis investment written charge income availableforsale securities ' unrealized loss recognized charge income removed accumulated comprehensive income loss aoci accounts receivable accounts receivable stated net realizable value allowance gross accounts receivable reflects best estimate probable losses inherent receivables portfolio determined basis historical experience specific allowances known troubled accounts currently available information accounts receivable written reasonable means collect full amount including litigation appropriate exhausted allowance million december million december inventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories net consist following december millions finished goods workinprocess materials inventories net property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years average depreciation period years five years equipment average depreciation period years leasehold improvements amortized life related facility lease including renewal periods appropriate asset whichever shorter depreciation expense years ended december million million million respectively equipment includes certain computer software software development costs incurred connection developing obtaining software internal use assets capital leases included property equipment combined balance sheets material litigation loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount recorded legal fees expensed incurred product liability abbvie accrues product liability claims undiscounted basis probable liability incurred amount liability reasonably estimated based existing information liabilities adjusted quarterly additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized business combinations results operations acquired companies included abbvie 's results operations respective acquisition dates assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill contingent consideration recognized estimated fair value acquisition date determined utilizing probability weighted discounted cash flow model subsequent changes fair value contingent payments recognized earnings allocation purchase price certain cases may subject revision based final determination fair value legal costs audit fees business valuation costs business acquisition costs expensed incurred goodwill intangible assets purchased intangible assets recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable impairment reviewed comparing projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset intangible asset written fair value usually discounted cash flow amount loss recorded equal excess asset 's net carrying value fair value cash flows identified individual asset review applied lowest level cash flows identifiable goodwill indefinitelived assets amortized subject impairment review annually whenever indicators impairment exist impairment goodwill would occur carrying amount reporting unit exceeded fair value reporting unit calculated using weighting income approach market approach fair value income approach calculated present value estimated cash flows discounted using riskfree market rate adjusted market participant 's view similar companies perceived risks cash flows fair value market approach calculated using market multiples peer groups applied operating results reporting units determine fair value implied fair value goodwill determined subtracting fair value identifiable net assets goodwill fair value reporting units impairment charge recorded excess carrying amount goodwill implied fair value based company 's recent annual impairment test performed third quarter fair value reporting units substantially excess carrying value indefinitelived assets tested impairment comparing fair value intangible asset carrying value value indefinitelived based present value projected cash flows using income approach carrying value exceeds fair value intangible asset considered impaired reduced fair value acquired inprocess research development initial costs rights acquired inprocess research development iprd projects acquired asset acquisition expensed iprd unless project alternative future use costs include initial payments incurred prior regulatory approval connection research development collaboration agreements provide rights develop manufacture market andor sell pharmaceutical products fair value iprd projects acquired business combination capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written development costs incurred acquisition expensed incurred indefinite definitelived assets subject impairment reviews discussed previously foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive income oci net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized earnings immaterial years presented derivatives derivative instruments recognized either assets liabilities fair value combined balance sheets classified current longterm based scheduled maturity instrument accounting changes fair value derivative instrument depends whether formally designated qualifies part hedging relationship applicable accounting standards type hedging relationship derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedge risk recognized earnings immediately fair value hedges used hedge interest rate risk associated certain company 's fixedrate debt effective portions changes fair value derivative designated cash flow hedge reported aoci subsequently recognized earnings consistent underlying hedged item cash flow hedges used manage exposures changes foreign currency exchange rates derivatives designated qualify hedges adjusted fair value current earnings determined derivative longer highly effective hedge company discontinues hedge accounting prospectively gains losses immediately reclassified aoci earnings relating hedged forecasted transactions longer probable occurring gains losses relating terminations effective cash flow hedges forecasted transactions still probable occurring deferred recognized consistent income loss recognition underlying hedged items terminations fair value hedge result cumulative fair value adjustment hedged items date termination amortized earnings remaining term hedged item derivatives including designated hedge principally classified operating section combined statements cash flows consistent underlying hedged item refer note information regarding abbvie 's derivative hedging activities earnings per share numerator basic diluted earnings per common share eps net earnings attributable abbvie denominator basic diluted eps based number shares abbvie common stock outstanding distribution date january distribution date abbott shareholders record close business december received one share abbvie common stock every one share abbott 's common stock held record date basic diluted earnings per common share average number common shares outstanding calculated using number abbvie common shares outstanding immediately following distribution number shares used calculate basic diluted earnings per share since abbvie equity awards outstanding prior distribution years ended december millions except per share amounts net earnings basic diluted earnings per common share basic diluted average shares outstanding note supplemental financial information interest expense net years ended december millions interest dividend income interest expense interest expense net income expense income expense net included income million resolution contractual agreement loss million impairment equity security income expense net included losses million million fair value adjustments accretion contingent consideration related acquisition solvay sa 's us pharmaceuticals business solvay income expense net also included ongoing contractual payments takeda associated conclusion tap pharmaceutical products inc joint venture accounts payable accrued liabilities december millions sales rebates accounts payable salaries wages commissions royalty license arrangements government investigation acquired iprd accounts payable accrued liabilities longterm liabilities december millions deferred income taxes pension postemployment benefits longterm liabilities accumulated comprehensive income loss netoftax components aoci component parent company equity follows december millions brackets denote loss cumulative foreign currency translation gain adjustments pension postemployment benefits cumulative unrealized gains marketable equity securities cumulative lossesgains derivative instruments designated cash flow hedges accumulated comprehensive loss note acquisitions collaborations arrangements cash outflows related acquisitions collaborations arrangements totaled million million billion respectively abbvie recorded iprd charges million million million respectively following significant acquisitions investments including licensing collaboration agreements require contingent milestone payments acquisitions solvay sa pharmaceuticals february abbvie acquired solvay certain product rights approximately billion cash plus contingent payments eur million per year certain sales milestones met total consideration valued billion includes billion cash payment plus estimated fair value milestonebased contingent payments approximately million estimated fair value contingent consideration based estimated probability achieving specified sales milestones discounted based expected timing payment subsequent changes fair value contingent payments recognized earnings transaction provides abbvie complementary pharmaceutical product portfolio including us rights androgel creon worldwide rights duodopa various research development projects abbvie acquired control business february financial results acquired operations included financial statements beginning date net sales acquired operations approximately billion solvay acquisition taken place january combined net sales net earnings would significantly different reported amounts acquisition funded cash shortterm investments allocation fair value arrangement acquisition date shown table billions acquired intangible assets nondeductible iprd nondeductible goodwill nondeductible deferred income taxes total consideration excess purchase price fair value assets acquired liabilities assumed approximately million recorded goodwill goodwill attributable expected synergies benefits abbvie believed would result acquisition acquired intangible assets consist primarily product rights currently marketed products amortized years average years acquired iprd projects accounted indefinitelived intangible assets regulatory approval discontinuation facet biotech corporation april abbvie acquired outstanding shares facet biotech corporation facet approximately million cash net cash held facet acquisition enhances abbvie 's earlyand midstage pharmaceutical pipeline including daclizumab biologic multiple sclerosis oncology compound substantial portion fair value acquisition including million daclizumab allocated acquired iprd projects accounted indefinitelived intangible assets regulatory approval discontinuation facet acquisition taken place january combined net sales net earnings would significantly different reported amounts collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements development stage expensed iprd subsequent payments made partner achievement milestones development stage expensed rd milestone achieved milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalty salesbased milestones expensed cost products sold incurred reata pharmaceuticals inc abbvie entered series transactions reata pharmaceuticals inc reata abbvie acquired equity interests reata million abbvie entered agreement acquire licensing rights outside united states excluding certain asian markets bardoxolone methyl product development treatment chronic kidney disease resulting charge iprd million achievement certain development milestones license agreement resulted charges million rd million iprd additional payments million could required achievement certain development regulatory milestones associated chronic kidney disease compound development fourth quarter abbvie entered collaboration reata joint development commercialization secondgeneration oral antioxidant inflammation modulators resulting charge iprd million paid first quarter october reata informed abbvie discontinuing phase iii clinical study bardoxolone methyl chronic kidney disease reata abbvie closely examine data study determine whether appropriate path forward development bardoxolone methyl chronic kidney disease indications fourth quarter abbvie recorded charge million income expense net impairment equity investment reata seattle genetics inc october abbvie recorded charge iprd million result entering twoyear collaboration agreement seattle genetics inc research develop commercialize three compounds antibodydrug conjugate approaches additional payments million licensed compound may required based achievement specified development regulatory commercial milestones agreement action pharma may abbvie recorded charge iprd million result acquisition abt previously referred ap drug development prevention acute kidney injury associated major cardiac surgery patients increased risk galapagos nv february abbvie recorded charge iprd million result entering global collaboration galapagos nv develop commercialize nextgeneration oral janus kinase jak inhibitor phase ii development potential treat multiple autoimmune diseases additional payments approximately billion could required achievement certain development regulatory commercial milestones agreement biotest ag june abbvie entered global agreement biotest ag develop commercialize anitcd treatment rheumatoid arthritis psoriasis resulting million charge iprd abbvie could future required make additional payments totaling million based achievement certain development regulatory commercial milestones agreement neurocrine biosciences inc june abbvie entered exclusive worldwide agreement neurocrine biosciences inc develop commercialize product treatment endometriosis resulting million charge iprd abbvie could future required make additional payments million based achievement certain development regulatory commercial milestones agreement note goodwill intangible assets carrying amount goodwill december million million respectively changes goodwill balance due foreign currency translation december accumulated goodwill impairment losses following table summarizes abbvie 's intangible assets december december gross net gross net carrying accumulated carrying carrying accumulated carrying millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived research development total intangible assets indefinitelived intangible assets relate iprd acquired business combination amortization expense million million million respectively abbvie recorded impairment charges million million respectively certain projects development charges included rd expenses december anticipated annual amortization expense intangible assets recorded december million million million million million intangible asset amortization included cost products sold combined statements earnings amortizable intangible assets amortized years average years developed product rights license agreements note restructuring plans prior years abbvie management approved plans realign worldwide manufacturing operations selected domestic international commercial rd operations order reduce costs abbvie recorded charge approximately million employee severance contractual obligations primarily related exit rd facility million classified rd million sga expenses abbvie recorded charge million reflecting employee severance related charges million classified cost products sold million rd million sga expenses following summarizes activity restructurings millions accrued balance december payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december additional million million million subsequently recorded respectively relating restructurings primarily accelerated depreciation solvay plans abbvie management approved restructuring plans primarily related acquisition solvay plan streamlined operations improved efficiencies reduced costs certain solvay sites functions well certain abbvie solvay commercial organizations various countries abbvie recorded charge million million classified cost products sold million classified rd million classified sga expenses following summarizes employee severance activity restructuring millions employee severance charge payments adjustments accrued balance december payments adjustments accrued balance december payments adjustments accrued balance december additional million million recorded respectively relating restructuring primarily accelerated depreciation asset impairments note debt credit facilities commitments contingencies longterm debt following summary longterm debt december effective interest rate millions floating rate notes due notes due notes due notes due notes due notes due fair value hedges unamortized bond discounts total longterm debt lease obligations current portion noncurrent portion excludes effect related interest rate swaps november abbvie issued billion aggregate principal amount senior notes approximately billion senior notes issued abbott partial consideration transfer assets abbott abbvie abbvie used part net proceeds sale senior notes senior notes issued abbott finance payment made november billion distribution abbott provided terms separation agreement debt guaranteed abbott abbvie separated abbott january abbvie may redeem senior notes series floating notes due time senior notes series floating notes due time time redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem floating notes due prior maturity debt issuance costs incurred connection senior note debt offering totaled million amortized respective terms notes interest expense combined statements earnings december company compliance senior note covenants shortterm borrowings december shortterm borrowings included billion commercial paper borrowings weightedaverage interest rate shortterm borrowings december abbvie billion unsecured bank credit facility agreement backs commercial paper program matures july abbott relieved obligations credit facility upon separation abbvie abbott january abbvie became sole obligor facility credit facility enables company borrow funds unsecured basis floating interest rates december company compliance credit facility covenants compensating balances commitment fees material leases part separation abbvie entered agreements lease certain facilities including office laboratory factory warehouse space principally noncancelable operating leases leases generally provide company pay taxes maintenance insurance operating costs leased property abbvie also leases office space shortterm basis typically cancelable operating leases company capital lease obligations principally automobiles december annual future minimum lease payments material future minimum lease payments longterm debt maturities years ended december millions later years total obligations commitments fair value hedges unamortized bond discounts current longterm debt lease obligations contingencies guarantees connection distribution abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures offbalance sheet arrangements specialpurpose entities activities included nonexchangetraded contracts accounted fair value ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable since abbvie longer maintains business relationship parties abbvie unable develop estimate maximum potential amount future payments obligations based upon past experience likelihood payments agreements remote abbvie periodically acquires business product rights abbvie agrees pay contingent consideration based attaining certain thresholds based occurrence certain events note financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations company 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative instruments reduce exposure foreign currency exchange rates company also exposed risk earnings cash flows could adversely impacted fluctuations interest rates company periodically enters interest rate swaps based judgment manage interest costs company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreedupon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts totaling billion million december respectively designated cash flow hedges recorded fair value accumulated gains losses december included cost products sold time products sold generally next twelve months company enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts markedtomarket resulting gains losses reflected income generally offset losses gains foreign currency exposure managed december abbvie held billion billion respectively foreign currency forward exchange contracts abbvie party interest rate hedge contracts designated fair value hedges totaling billion december effect hedge change fixedrate interest obligation floating rate portion debt abbvie recorded contracts fair value adjusted carrying amount fixed rate debt offsetting amount following table summarizes amounts location abbvie 's derivative instruments december fair valueassets fair valueliabilities millions balance sheet caption balance sheet caption interest rate swaps designated fair value hedges longterm liabilities foreign currency forward exchange contracts prepaid expenses accounts payable accrued hedging instruments liabilities prepaid expenses accounts payable accrued others designated hedges liabilities total following table summarizes activity derivative instruments amounts location income expense gain loss reclassified income certain derivative instruments years ended december amount hedge ineffectiveness significant loss gain recognized income expense gain loss comprehensive reclassified loss income income millions income statement caption foreign currency forward exchange contracts designated cash flow hedges cost products sold net foreign exchange gain designated hedges na na na loss interest rate swaps designated fair value hedges na na na interest expense net loss million related fair value hedges recognized net interest expense offset equally million gains underlying hedged item fixedrate debt fair value measures fair value hierarchy accounting standard fair value measurements consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis combined balance sheets december basis fair value measurement quoted prices active significant markets significant balance identical observable unobservable december assets inputs inputs millions level level level assets cash equivalents certificates deposit us treasury securities equity securities foreign currency forward contracts total assets liabilities interest rate hedges foreign currency forward contracts contingent consideration total liabilities basis fair value measurement quoted prices active significant markets significant balance identical observable unobservable december assets inputs inputs millions level level level assets cash equivalents us treasury securities equity securities foreign currency forward contracts total assets liabilities foreign currency forward contracts contingent consideration total liabilities availableforsale equity securities consist investments fair value determined using published market price per unit multiplied number units held without consideration transaction costs derivatives entered company valued using publicized spot forward prices foreign currency hedges publicized swap curves interest rate hedges contingent payments valued using discounted cash flow technique reflects management 's expectations probability payment gross unrealized holding gains availableforsale equity securities totaled million million december respectively transfers assets liabilities fair value measurement levels following table reconciliation fair value measurements use significant unobservable inputs level consist contingent payments related acquisitions millions fair value december loss recognized earnings fair value december payments loss recognized earnings fair value december connection acquisition solvay 's us pharmaceuticals business achievement certain sales milestone resulted payment approximately million liability previously established addition financial instruments company required recognize fair value combined balance sheets company certain financial instruments recognized historical cost basis fair value carrying values fair values certain financial instruments december shown table approximate book values fair values millions assets investments liabilities shortterm borrowings current maturities longterm debt lease obligations longterm debt lease obligations following table summarizes bases used measure approximate fair values financial instruments december basis fair value measurement quoted prices active significant markets significant fair value identical observable unobservable december assets inputs inputs millions level level level assets investments total assets liabilities shortterm borrowings current maturities longterm debt lease obligations longterm debt lease obligations total liabilities investments consist cost method investments heldtomaturity debt securities determining fair value cost method investments company takes consideration recent transactions well financial information investee represents level basis fair value measurement fair value heldtomaturity debt securities longterm debt estimated based upon quoted market prices similar debt instruments fair values shortterm current borrowings approximate carrying values due short maturities instruments material adjustments fair value years ended december assets liabilities measured fair value recurring basis except discussed note regarding impairment company 's investment reata counterparties financial instruments consist select major international financial institutions concentrations risk company invests excess cash time deposits money market funds us treasury securities diversifies concentration cash among different financial institutions company monitors concentrations credit risk associated deposits financial institutions credit exposure limits established limit concentration single issuer institution three us wholesalers accounted percent percent total net accounts receivables december respectively substantially abbvie 's us sales three wholesalers addition governmental accounts greece portugal italy spain accounted percent percent total net accounts receivable december respectively note postemployment benefits abbott sponsored plans abbvie employees participated certain us international defined benefit pension postemployment plans sponsored abbott plans included participants abbott 's businesses accounted multiemployer plans abbvie 's combined financial statements result asset liability recorded abbvie historical balance sheets december recognize funded status plans abbott made voluntary contributions defined benefit pension funds abbvie accounts multiemployer plans totaling million million million respectively multiemployer pension plans approximately percent percent funded december respectively connection separation abbvie abbott january plans separated abbott transfer certain liabilities assets plans abbvie estimated amounts assumed abbvie shown table defined postemployment millions benefit plans plans accumulated benefit obligations deferred losses projected benefit obligations fair value assets net liability abbott sponsored defined benefit postemployment benefit plans abbvie recorded expenses million million abbvie sponsored plans abbvie sole sponsor certain defined benefit pension postemployment plans reflected combined balance sheets december preparation separation abbott certain pension postemployment benefit plans assumed abbvie reflected december combined balance sheet abbvie made voluntary contributions abbvie sponsored pension plans million million million respectively first quarter abbvie made voluntary contribution million main domestic defined benefit pension plan assumed benefit plan information table pertains abbvie sponsored pension postemployment plans defined postemployment benefit plans plans years ended december millions projected benefit obligations beginning period service cost interest cost assumption plan liabilities actuarial loss gain benefits paid primarily foreign currency translation loss gain end period fair value plan assets beginning period actual return plans assets company contributions assumption plan assets benefits paid end period funded status december amounts recognized combined balance sheets assets current liabilities longterm liabilities net liability december actuarial losses net prior service cost aoci december projected benefit obligations pbo table included billion million december respectively related international defined benefit pension plans generally funded accordance local regulations benefit payments plans funded company assets plans reflected table accumulated benefit obligations abo billion million december respectively plans reflected table abo exceeded plan assets december abo pbo aggregate plan assets million billion million respectively amounts recognized aoci oci pension postemployment plans ' gains losses prior service costs credits yet recognized net periodic benefit cost recognized netoftax basis aoci amortized net periodic benefit cost future following summary pretax losses included oci millions actuarial loss prior service cost amortization prior service cost actuarial losses foreign exchange loss total pretax loss recognized oci december actuarial loss amortization prior service cost actuarial losses foreign exchange loss total pretax loss recognized oci december pretax amount actuarial losses prior service cost included aoci december expected recognized net periodic benefit cost million defined benefit plans million postemployment plans net periodic benefit cost years ended december millions service cost interest cost expected return plans assets amortization actuarial losses prior service costs net periodic pension benefit cost weightedaverage assumptions used determining benefit obligations measurement date discount rate rate compensation increases assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost discount rate expected longterm rate return plan assets expected rate change compensation pension plan assets basis fair value measurement quoted prices significant significant balance active markets observable unobservable december identical assets inputs inputs millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentse government securities international absolute return fundsf real assets otherg fair value plan assets basis fair value measurement quoted prices significant significant balance active markets observable unobservable december identical assets inputs inputs millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentse absolute return fundsf otherg fair value plan assets mix index funds track sp percent percent separate actively managed equity accounts benchmarked russell percent percent b mix index funds percent separate actively managed equity accounts percent track benchmarked sp midcap index c primarily separate actively managed pooled investment accounts benchmarked msci emerging market various local indices index funds percent percent separate actively managed accounts percent percent e index funds percent percent separate actively managed accounts percent percent f primarily funds invested managers global mandate flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities interest rate futures currencies securities outperform agreed upon benchmark specific return volatility targets g primarily investments liquid commodity future contracts private energy funds cash cash equivalents equities valued using quoted prices valued published market prices equities common collective trust registered investment company valued using significant observable inputs valued net asset value nav provided fund administrator nav based value underlying assets owned fund minus liabilities fixed income securities valued using significant observable inputs valued prices obtained independent financial service industryrecognized vendors absolute return funds commodities valued nav provided fund administrator following table summarizes change value plan assets measured using significant unobservable inputs level millions january transfers categories actual return plan assets hand year end purchases sales settlements net december investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality known significant concentrations risk plans ' assets plans ' expected return assets shown based management 's expectations longterm average rates return achieved underlying investment portfolios establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected pension postemployment payments defined postemployment millions benefit plans plans table reflects total benefit payments expected paid participants includes payments funded company assets well paid plans abbvie employees also participate abbott laboratories stock retirement plan abbott 's principal defined contribution plan abbvie recorded expense million million million years ended december respectively related plan abbvie provides certain postemployment benefits primarily salary continuation plans qualifying employees accrues related cost service lives employees note stockbased compensation prior separation abbvie employees participated abbott 's incentive stock program conjunction separation company adopted abbvie incentive stock program provides assumption certain awards granted abbott incentive stock program authorizes grant several different forms benefits including nonqualified stock options restricted stock awards rsas restricted stock units rsus abbvie incentive stock program initially reserved million shares common stock issuance respect awards participants subsequent yearend reserve reduced approximately million shares stock option rsa rsu awards granted abbvie 's board directors following disclosures represent portion abbott 's incentive stock program abbvie employees participated awards granted program consisted abbott common shares related equity account balances reflected abbott 's consolidated statements stockholders ' equity reflected abbvie 's combined financial statements abbvie 's combined statements earnings reflects compensation expense stockbased awards associated portion abbott 's incentive stock program abbvie employees participated accordingly amounts presented necessarily indicative future performance necessarily reflect results abbvie would experienced independent publiclytraded company periods presented equity award amounts presented converted reflect separation abbott upon separation january holders abbott stock options rsas rsus generally received one abbvie stockbased award abbott stockbased award outstanding value combined abbott abbvie stockbased awards separation designed generally preserve intrinsic value fair value award immediately prior separation per share data presented note adjusted reflect impact separation stock compensation expense stock compensation expense recognized combined statements earnings million million million respectively related tax benefit recognized million million million respectively half stockcompensation expense classified sga remainder classified rd cost products sold compensation costs capitalized combined balance sheets december significant compensation expense stockbased awards measured based fair value awards date sharebased awards granted adjusted estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible charge compensation expense stockbased awards granted retirementeligible employees compensation expense recognized immediately grant date employee able retain award without continuing provide service stock options exercise price options granted least equal percent market value date grant stock options typically contractual term years generally vest onethird increments threeyear period except options replacement feature pre options granted replacement option feature terms conditions replacement option material respects applicable original grant exercise price option replacement option feature paid common shares held employee replacement option granted number shares used make payment closing price common share business day exercise used determine number shares required exercise related option exercise price replacement option replacement option exercisable full six months date grant term expiring expiration date original option fair value stock options determined using blackscholes model weightedaverage assumptions used estimating fair value stock options granted year along weightedaverage grantdate fair values follows years ended december riskfree interest rate average life options years volatility dividend yield fair value per stock option riskfree interest rate based rates available time grant zerocoupon us government issues remaining term equal option 's expected life average life option based historical projected exercise lapsing data expected volatility based implied volatilities traded options abbott 's stock historical volatility abbott 's stock expected life option dividend yield based option 's exercise price annual dividend rate time grant following table summarizes stock option activity year ended december stock option outstanding balances december abbott 's incentive stock programs abbvie employees weighted weighted options thousands aggregate intrinsic average average remaining aggregate value millions options exercise price life years intrinsic value outstanding december granted exercised lapsed outstanding december exercisable december aggregate intrinsic value table represents difference exercise price closing stock price last day trading year total intrinsic value options exercised million million million respectively december million unrecognized compensation cost related stock options expected recognized expense next three years rsas rsus restricted stock awards generally vest three five years restricted stock awards vest five years onethird award vests one year rsus vest three years upon vesting recipient receives one share common stock vested restricted stock unit fair value rsas rsus determined based number shares granted quoted price common stock date grant following table summarizes rsas rsus balances activity abbott 's incentive stock programs abbvie employees weighted average share units thousands share units grant date fair value nonvested shares december granted vested lapsed nonvested shares december fair market value restricted stock awards units vested million million million respectively december million unrecognized compensation cost related rsas rsus expected recognized expense next three years note income taxes earnings income taxes years ended december millions domestic foreign total earnings income taxes income taxes years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income taxes effective tax rate reconciliation years ended december millions statutory tax rate benefit lower tax rates tax exemptions primarily puerto rico resolution certain tax positions pertaining prior years effect nondeductible litigation loss accrual puerto rico excise tax credit state taxes net federal benefit net effective tax rate income taxes included recognition tax benefits totaling approximately million million respectively result favorable resolutions various tax positions pertaining prior years income taxes also reflected nondeductibility litigation reserve excluding discrete items effective tax rates less statutory us federal income tax rate percent principally due benefit lower statutory tax rates tax exemptions puerto rico foreign taxing jurisdictions reduced tax rates percentage points respectively puerto rico enacted legislation assesses excise tax beginning certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold combined statements earnings majority tax creditable us income tax purposes excise tax totaled approximately million million respectively december us income taxes provided approximately billion undistributed foreign earnings earnings indefinitely reinvested continued use foreign operations practicable determine amount deferred income taxes provided earnings deferred tax assets liabilities december millions deferred tax assets compensation employee benefits trade receivable reserves inventory reserves deferred intercompany profit state income taxes total deferred tax assets deferred tax liabilities depreciation primarily excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax asset unrecognized tax benefits years ended december millions january increase due current year tax positions increase due prior year tax positions decrease due current year tax positions decrease due prior year tax positions settlements december abbvie abbott entered tax sharing agreement effective date separation tax contingencies prior separation abbott indemnify hold abbvie harmless tax positions settled amounts excess recorded liabilities abbvie benefit prior tax positions resolved favorably recorded amounts result liability uncertain tax positions recorded combined financial statements december note litigation number patent disputes third parties claim abbvie 's products infringe patents february us supreme court denied centocor inc 's new york university 's petition review february federal circuit court appeals decision reversing billion judgment favor centocor new york university patent claimed abbvie 's humira infringed decision concludes case us department justice us attorney western district virginia various state attorneys general investigated abbvie 's sales marketing activities depakote government sought determine whether activities violated civil andor criminal laws including federal false claims act food drug cosmetic act antikickback statute connection medicare andor medicaid reimbursement third parties state attorneys general offices sought determine whether activities violated various state laws including state consumer fraudprotection statutes abbvie recorded charges billion third quarter million first quarter related civil criminal claims arising matter may abbvie reached resolution depakoterelated federal claims medicaidrelated claims states district columbia consumer protection claims states district columbia abbvie paid approximately billion settlement payments material abbvie 's cash flows recorded accrual balance litigation december significant within next year legal proceedings may occur may result change estimated loss accrued abbvie feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvie 's financial position cash flows results operations note related party transactions abbott historical financial statements abbott provided abbvie certain services included administration treasury payroll employee compensation benefits travel meeting services public investor relations real estate services internal audit telecommunications information technology corporate income tax selected legal services services provided abbvie temporary basis separation financial information combined financial statements necessarily include expenses would incurred abbvie separate standalone entity financial information herein may necessarily reflect combined financial position results operations cash flows abbvie future would abbvie separate standalone entity periods presented management believes methods used allocate expenses abbvie reasonable allocation methods included relative sales headcount square footage number transactions measures allocations totaled million million million years ended december respectively abbvie incurred million separationrelated expenses including legal information technology regulatory fees principally classified sga december outstanding intercompany transactions abbvie abbott reflected due abbott laboratories due abbott laboratories combined balance sheet note segment geographic area information abbvie operates one business segmentpharmaceutical products substantially abbvie 's us sales three wholesalers outside united states products sold primarily health care providers distributors depending market served net sales key products follows years ended december millions humira androgel tricortrilipix kaletra niaspan synagis lupron sevoflurane synthroid norvir zemplar creon net sales net sales external customers based country sold product follows years ended december millions united states netherlands germany japan united kingdom spain france canada brazil italy countries net sales longlived assets consisting net property equipment united states puerto rico totaled approximately billion billion december respectively note quarterly financial data unaudited millions except per share data first quarter net sales gross margin net earnings basic diluted earnings per share second quarter net sales gross margin net earnings basic diluted earnings per share third quarter net sales gross margin net earnings basic diluted earnings per share fourth quarter net sales gross margin net earnings basic diluted earnings per share computation basic diluted earnings per share periods calculated using shares distributed january report independent registered public accounting firm board directors shareholders abbvie inc audited accompanying combined balance sheets abbvie inc subsidiaries company december related combined statements earnings comprehensive income statement parent company equity cash flows three years period ended december combined financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits accordance auditing standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether combined financial statements free material misstatement company required engaged perform audit internal control financial reporting audits included consideration internal control financial reporting basis designing audit procedures appropriate circumstances purpose expressing opinion effectiveness company 's internal control financial reporting accordingly express opinion audit also includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion combined financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america described note accompanying combined financial statements derived consolidated financial statements accounting records abbott laboratories combined financial statements also include expense allocations certain corporate functions historically provided abbott laboratories allocations may reflective actual expense would incurred company operated separate legal entity apart abbott laboratories deloitte touche llp chicago illinois march item changes disagreements accountants accounting financial disclosure previously reported abbvie 's current report form k dated december audit committee abbvie 's board directors approved dismissal deloitte touche llp deloitte abbvie 's independent registered public accountant effective date deloitte 's completion audit services fiscal year ending december filing abbvie 's annual report securities exchange commission approved appointment ernst young llp abbvie 's independent registered public accounting firm perform independent audit services beginning fiscal year ending december fiscal years ended december march disagreements term defined item aiv regulation sk related instructions abbvie deloitte matter accounting principles practices financial statement disclosure auditing scope procedure resolved satisfaction deloitte would caused deloitte make reference subject matter disagreement connection reports abbvie 's combined financial statements years ii reportable events term defined item av regulation sk item controls procedures disclosure controls procedures evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer william j chase evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure internal control financial reporting management 's annual report internal control financial reporting annual report include report management 's assessment regarding internal control financial reporting attestation report company 's registered public accounting firm due transition period established rules sec newly public companies changes internal control financial reporting quarter ended december changes abbvie 's internal control financial reporting defined rule af exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect error fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures item b information none part iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors section beneficial ownership reporting compliance procedure recommendation nomination directors transaction business annual meeting included abbvie inc proxy statement proxy statement filed march also incorporated herein reference text found caption executive officers registrant pages hereof abbvie 's code business conduct requires business activities conducted compliance laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports chief executive officer public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference proxy statement filed march item security ownership certain beneficial owners management related stockholder matters equity compensation plan information abbvie outstanding shares issued company equity compensation plan december b information concerning security ownership incorporated herein reference material heading ownership securitiessecurity ownership executive officers directors proxy statement proxy statement filed march item certain relationships related transactions director independence material included proxy statement headings board directors committees corporate governance materials procedures approval related person transactions transactions abbott incorporated herein reference proxy statement filed march item principal accounting fees services material included proxy statement headings audit informationaudit fees nonaudit fees audit information policy audit committee preapproval audit permissible nonaudit services independent auditor incorporated herein reference proxy statement filed march part iv item